2025 EALA Rising Star Bootcamp

Date: May 23(Fri.) - 24 (Sat.), 2025
Venue: National Taiwan University College of Medicine (NTUCM), Taipei, Taiwan

Day 1 (May 23, 2025, Friday)

National Taiwan University College of Medicine Lecture Hall 103/203/204/NTUH 5F Cardiovascular Center Conference Room

Time	Topic	Speaker	Moderator	Lecture Hall
12:50-	Registration			103
13:10-13:20	Welcome and Overview • Review the purpose and goals of the program	Chun-Jen Liu		
13:20-14:00	Young Investigators Introduction (1-2 minutes): 1. Name and institution 2. Current position 3. Former and/or current research mentor(s) 4. Current field of research 5. What do you like to do outside of hepatology	YI	Tung-Hung Su	
14:00-14:20 14:20-14:30 (Q&A)	Why an academic career is worth pursuing-personal story of challenges and successes	W. Ray Kim	Chun-Jen Liu	
14:30-14:50 14:50-15:00 (Q&A)	Cohort, case-control, and clinical trials: Designing studies for high-quality real-world evidence	Hayato Hikita	Mei-Hsuan Lee	
15:00-15:20 15:20-15:30 (Q&A)	Statistics for non-statisticians: Bridging clinical insight with AI-enhanced learning	Mei-Hsuan Lee	Seung Up Kim	
15:30-15:50	Group photos for Day 1 / Break and connections			
15:50-17:00	Small group discussion for YI project proposal, comments by mentors 1. Network with other participants in the small group to share a common research interest 2. Collaborate with small group members to propose a joint research project and present it on Day2 (title/background and aims/materials and methods/collaboration potential), comments by YI mentors 3. Building connections by LINE or WhatsApp			
	Group 1: Viral Hepatitis	YI	Tatsuya Kanto Wen-Juei Jeng	103
	Group 2: MASLD	YI	Takumi Kawaguchi Jee-Fu Huang	203
	Group 3: Cirrhosis	YI	Moon Young Kim Kuei-Chuan Lee	204
	Group 4: HCC	YI	Do Young Kim Yi-Hsiang Huang	NTUH 5F CV Conf Room
17:00-17:10	Wrap up for Day 1 and orientation for Day 2	Tung-Hung Su		103
17:30-20:30	Faculty Dinner (Regent Taipei Hotel, by shuttle bus)			

2025 EALA Rising Star Bootcamp

Date: May 23(Fri.) - 24 (Sat.), 2025
Venue: National Taiwan University College of Medicine (NTUCM), Taipei, Taiwan

Day 2 (May 24, 2025, Saturday)

National Taiwan University College of Medicine Lecture Hall 503/504/505/NTUH 5F Cardiovascular Center Conference Room

Time	Topic	Speaker	Moderator	Lecture Hall
07:50-	Registration			NTUH 5F CV Conf Room
08:00-08:20 08:20-08:30 (Q&A)	Scientific communication: Presentation skills	Wonseok Kang	Tatsuya Kanto	
08:30-08:50 08:50-09:00 (Q&A)	How to do wet bench research and manage your lab?	Tetsuo Takehara	Su Jong Yu	
09:00-09:20 09:20-09:30 (Q&A)	How to publish high-impact papers in good journals?	Won Kim	Ming-Lung Yu	
09:30-09:50 09:50-10:00 (Q&A)	Leadership skills: How to build and manage your team? How to become a mentor?	Ming-Lung Yu	Tetsuo Takehara	
10:00-10:10	Break, connections, and change rooms			
10:10-10:50	Small group discussion for YI project proposal, comments by mentors 1. Summary of comments from Day 1 and lessons learned 2. Revisions of the proposal based on the comments 3. Opportunities for possible collaboration			
	Group 1: Viral Hepatitis	YI	Tatsuya Kanto Wen-Juei Jeng	503
	Group 2: MASLD	YI	Takumi Kawaguchi Jee-Fu Huang	504
	Group 3: Cirrhosis	YI	Moon Young Kim Kuei-Chuan Lee	505
	Group 4: HCC	YI	Do Young Kim Yi-Hsiang Huang	NTUH 5F CV Conf Room
10:50-11:00	Break, connections, and change rooms			
11:00-12:00	Small group final presentation of projects (all groups 10 min + 5 min Q&A) 1. Title 2. Background and aims 3. Materials and methods 4. Any collaboration potential	YI	Tung-Hung Su	NTUH 5F CV Conf Room
12:00-12:10	Wrap-up and closing remarks Group Photo for Day 2	Chun-Jen Liu		
12:30-13:30	Lunch (Chang Yun-Fa Foundation International Convention Center)			

Speaker

	Topic	Name	Affiliations	Email
1	Why an academic career is worth pursuing - personal story of challenges and successes	W. Ray Kim	Mayo Clinic Arizona, USA	Kim.Ray@mayo.edu
2	Cohort, case-control, and clinical trials: Designing studies for high-quality real-world evidence	Hayato Hikita	Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan	hikita@gh.med.osaka-u.ac.jp
3	Statistics for non-statisticians: Bridging clinical insight with AI-enhanced learning	Mei-Hsuan Lee	National Yang Ming Chiao Tung University, Taipei, Taiwan	meihlee@nycu.edu.tw
4	Scientific communication: presentation skills	Wonseok Kang	Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea	wskang.md@gmail.com
5	How to do wet bench research and and manage your lab?	Tetsuo Takehara	Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan	takehara@gh.med.osaka-u.ac.jp
6	How to publish high-impact papers in good journals?	Won Kim	Seoul National University, College of Medicine, Seoul, Korea	wonshiri@hanmail.net
7	Leadership skills: How to build and manage your team? How to become a mentor?	Ming-Lung Yu	Kaohsiung Medical University, Kaohsiung, Taiwan	fish6069@gmail.com

Young Investigators Mentors

	Name	Affiliations	Email
TW1	Wen-Juei Jeng (VH)	Linkou Chang Gung Memorial Hospital, Taipei, Taiwan	rachel.jeng@gmail.com
TW2	Jee-Fu Huang (MASLD)	Kaohsiung Medical University, Kaohsiung, Taiwan	jf71218@gmail.com
TW3	Kuei-Chuan Lee (Cirrhosis)	Taipei Veterans General Hospital, Taipei, Taiwan	kclee2@vghtpe.gov.tw
TW4	Yi-Hsiang Huang (HCC)	Taipei Veterans General Hospital, Taipei, Taiwan	yhhuang@vghtpe.gov.tw
JP1	Tatsuya Kanto (VH)	The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan	kanto.t@jihs.go.jp
JP2	Takumi Kawaguchi (MASLD)	Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine	takumi@med.kurume-u.ac.jp
KR1	Moon Young Kim (Cirrhosis)	Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea	drkimmy@yonsei.ac.kr
KR2	Do Young Kim (HCC)	Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea	dyk1025@yuhs.ac

YI from Taiwan

	Name	Affiliations	Group	Email
1	Shang-Chin Huang	National Taiwan University Hospital, Bei-Hu branch	MASLD	chin780508@gmail.com
2	Kai-Chi Chang	National Taiwan University Hospital	MASLD	kaichichang@ntu.edu.tw
3	Hung-Wei Wang	China Medical University Hospital, Taichung	HCC	sdqw190@gmail.com
4	Shih-Chieh Chien	National Cheng Kung University Hospital	MASLD	slamdunk9031137@gmail.com
5	Yen-Chun Liu	Chang Gung Memorial Hospital, Linkou medical center, Taoyuan, Taiwan	Viral Hepatitis	yenchun923@gmail.com
6	Tyng-Yuan Jang	Kaohsiung Medical University Hospital, Kaohsiung, Taiwan	Cirrhosis	sls0902000@gmail.com
7	Shu-Hsien Lin	Chia-Yi Christian Hospital, Chia-Yi, Taiwan	HCC	linsusan77628@gmail.com
8	Yun-Cheng Hsieh	Taipei Veterans General Hospital, Taipei, Taiwan	Cirrhosis	ychsieh7@vghtpe.gov.tw
9	Hsin-Ju Tsai	Taichung Veterans General Hospital, Taichung, Taiwan	Viral Hepatitis	a9194024@hotmail.com
10	Yu-Ju Wei	Kaohsiung Medical University Hospital, Kaohsiung, Taiwan	Cirrhosis	weiyuju@gmail.com

YI from Japan

	Name	Affiliations	Group	Email
1	Yuki Tahata	Osaka University	Viral Hepatitis	yuki.tahata@gh.med.osaka-u.ac.jp
2	Takao Miwa	Gifu University	Cirrhosis	miwa.takao.a6@f.gifu-u.ac.jp
3	Norihiro Imai	Nagoya University	MASLD	norihiro.imai@gmail.com
4	Kazuya Okushin	The University of Tokyo	Viral Hepatitis	kazuyaoxin@g.ecc.u-tokyo.ac.jp
5	Keisuke Koroki	Chiba University	HCC	koroki-keisuke@chiba-u.jp
6	Tomoaki Yoh	Kyoto University	HCC	tomyoh@kuhp.kyoto-u.ac.jp

YI from Korea

	Name	Affiliations	Group	Email
1	Jeong-Ju Yoo	Soonchunhyang University	Viral Hepatitis	puby17@naver.com
2	Han Ah Lee	Chung-Ang University	MASLD	amelia86@naver.com
3	Soon Kyu Lee	The Catholic University	HCC	blackiqq@catholic.ac.kr
4	Won-Mook Choi	University of Ulsan	Viral Hepatitis	dr.choi85@gmail.com
5	Young-Sun Lee	Korea University	MASLD	lys810@korea.ac.kr
6	Yeonjung Ha	CHA University	HCC	yeonjung.ha@gmail.com
6	Soon Sun Kim	Ajou University	Cirrhosis	cocorico99@gmail.com

YI groups

Viral Hepatitis	MASLD	Cirrhosis	HCC
Mentors			
Tatsuya Kanto	Takumi Kawaguchi	Moon Young Kim	Do Young Kim
Wen-Juei Jeng	Jee-Fu Huang	Kuei-Chuan Lee	Yi-Hsiang Huang
YI			
Yuki Tahata	Norihiro Imai	Takao Miwa	Keisuke Koroki
Kazuya Okushin	Han Ah Lee	Soon Sun Kim	Tomoaki Yoh
Jeong-Ju Yoo	Young-Sun Lee	Tyng-Yuan Jang	Soon Kyu Lee
Won-Mook Choi	Shang-Chin Huang	Yun-Cheng Hsieh	Yeonjung Ha
Yen-Chun Liu	Kai-Chi Chang	Yu-Ju Wei	Hung-Wei Wang
Hsin-Ju Tsai	Shih-Chieh Chien		Shu-Hsien Lin

Moderator



Tung-Hung Su

AFFILIATION / INSTITUTION
National Taiwan University Hospital

POSITION
Clinical Professor

BRIEF INTRODUCTION
Dr. Tung-Hung Su earned his M.D. degree from the National Taiwan University College of Medicine in 2001 and his Ph.D. from the Graduate Institute of Clinical Medicine at the same university in 2015. He has been an attending physician specializing in Hepatology and a Clinical Professor in the Department of Internal Medicine at National Taiwan University Hospital since 2024. From 2017 to 2019, he was a visiting scholar at Stanford University. Dr. Su's research focuses on translational studies on liver fibrosis treatment, viral hepatitis B management, cirrhosis, and hepatocellular carcinoma, including disease prediction and outcome research using large-scale electrical medical records. Additionally, he applies artificial intelligence models to the study of liver diseases. He has published several research papers in these fields.

RESEARCH INTERESTS
Management of viral hepatitis, cirrhosis, Surveillance of hepatocellular carcinoma, Artificial intelligence for liver diseases

REPRESENTATIVE PUBLICATIONS
1. Su TH, Wu CH, Kao JH. Artificial intelligence in precision medicine in hepatology. J Gastroenterol Hepatol. 2021 Mar;36(3):569-580
2. Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liao SH, Hong CM, Liu CH, Lan TY, Yang HC, Liu CJ, Chen PJ, Kao JH. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B. Hepatol Int. 2023 Oct;17(5):1139-1149.
3. Huang SC, Su TH, Tseng TC, Hsu SJ, Hong CM, Lan TY, Liu CH, Yang HC, Liu CJ, Kao JH. All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease. J Hepatol. 2024 Dec 14:S0168-8278(24)02763-6
4. Chang KC, Su TH, Wu CK, Huang SC, Tseng TC, Hong CM, Hsu SJ, Liu CH, Yang HC, Liu CJ, Kao JH. Metabolic dysfunction-associated steatotic liver disease is associated with increased risks of heart failure. Eur J Heart Fail. 2025 Jan 8. doi: 10.1002/ejhf.3567
5. Su TH, Yang SS, Lee MH, Kao WY, Huang SC, Chen FF, Poon FS, Tsai LW, Chen YT, Lin C, Wang W, Kim WR, Kao JH. High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction associated steatotic liver disease. Clin Mol Hepatol. 2025 Jan 6. doi: 10.3350/cmh.2024.0822

Moderator

Chun-Jen Liu

Chun-Jen Liu is a Professor at the Department of Internal Medicine, National Taiwan University College of Medicine, and Director of the Hepatitis Research Center, Director of Gastroenterology & Hepatology, and Director of Clinical Trial Center, National Taiwan University Hospital. He achieved his MD and PhD at the National Taiwan University. Professor LIU's interests are in chronic hepatitis B and C, HCC, and nonalcoholic fatty liver disease, where his studies focus on the role of viral and host factors in the pathogenesis and treatment of chronic viral hepatitis, NAFLD and HCC. He has been actively involved in clinical trials for the treatment of chronic hepatitis C, chronic hepatitis B, HBV/HCV co-infection, NASH and hepatocellular carcinoma, and delivered the JGH Foundation Emerging Leader Lecture in APDW 2013. He is now the associate editor of the Journal of the Formosan Medical Association and Journal of Microbiology, Immunology and Infection. He has authored 380 papers in international, peer-reviewed journals including Gastroenterology, Hepatology, Gut, Journal of Hepatology, Clinical Infectious Diseases and Clinical Gastroenterology and Hepatology.

RESEARCH INTERESTS

Hepatitis B, Hepatitis C, HCC, and Steatotic liver disease

REPRESENTATIVE PUBLICATIONS

1. Liu CJ, Chen PJ, Lai MY, Kao JH, Chang CF, Wu HL, Shau WY, Chen DS. A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. Gastroenterology 2003;124:80-90.
2. Liu CJ, Lo SC, Kao JH, Tseng PT, Lai MY, Ni YH, Yeh SH, Chen PJ, Chen DS. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol 2006;44:39-46.
3. Liu CJ, Lee PH, Lin DY, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and dose-finding. J Hepatol 2009;50:958-968.
4. Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis C and B viruses. Gastroenterology 2009;136:496-504.
5. Liu CJ, Chuang WL, Sheen IS, et al. Efficacy of ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected with HBV. Gastroenterology 2018;154:989-997

Speaker

W. Ray Kim

W. Ray Kim, MD, MBA, FAASLD, Professor of Medicine at Mayo Clinic Arizona, Scottsdale, AZ

Dr. Kim received his MD degree from Seoul National University and his MBA from the University of Pennsylvania. Following his medicine residency at Seoul National University and the University of Arkansas, he underwent gastroenterology and hepatology fellowship training at Mayo Clinic in Minnesota. Subsequently, Ray joined the faculty of the Mayo College of Medicine, where he established his research in prognostication in patients with chronic liver disease. He is best known for his work in developing, validating and refining the Model for End-stage Liver Disease (MELD) score.

In 2013, he was recruited to Stanford University to lead the Division of Gastroenterology and Hepatology. Under his leadership, the Division prospered with a significant growth in the breadth and depth of faculty and their expertise, innovative educational programs for the GI, liver and other advanced fellowships, excellence in scientific scholarship and supportive community with emphasis on mentorship and individual growth.

After serving as the GI Chief at Stanford for nearly 11 years, he is returning to Mayo to create the Center for Policy and Outcomes Research in Transplantation (CPORT) based in the Arizona campus.

Why an academic career is worth pursuing – personal story of challenges and successes

W. Ray Kim

Medicine is a science of uncertainty and an art of probability.

William Osler

Being a physician is an honor when we are able to lessen the suffering of our fellow human beings. Being a physician scientist is a privilege because we may help discover new information with which we can change medical practice, save lives and alleviate sickness on a much larger scale.

In Figure 1, from the point of view of a career, the rewards of academic medicine may start with scientific contributions that may translate to benefits to our patients. Meaningful scientific achievements may earn us opportunities to serve as a leader within and outside our own institutions. Over time, these experiences become invaluable resources to help develop physician-scientist-leaders of the next generation.



An academic physician's career is demarcated by several milestones. Figure 2 summarizes what may motivate an academic physician to work towards his/her professional growth. Some of the motivations are meaningful and helpful, while others are less so.



It is often said that the key ingredients of success in academic medicine are grants and papers. The eco system in academic medicine includes a feedback loop that scientific discoveries are documented in publications, which fuel research funding to allow continuing the research. Then, it is clear that for it to work, there needs to be a functional peer review process to make sure that new insights are given space in scientific journals. It is also important that there is not only available funding, but also fair and intelligent system to identify worthy investigations and researchers to support. A young physician scientist needs to break into this system somehow, which emphasizes the importance of effective mentorship that is necessary to equip the person with knowledge, experience, resources and connections, all necessary ingredients for a young investigator to have a realistic chance to launch a career towards long term success.

Overtime, progression in the person's academic career leads to practical benefits such as promotion in the rank, which is often accompanied by increased compensation. At certain universities, a tenure provides more security in the position and compensation. Receiving honors and awards from professional societies and academic institutions in acknowledgement of significant achievements elevates the person's stature as an academician.

On the other hand, other 'rewards' such as reputation and influence, especially if it is directed towards own benefits, are often more of a distraction than true benefits of academic medicine. There is nothing wrong with accumulating wealth and seeking financial security, but they can also potentially be unproductive if they get in the way of achieving the scientific mission.

Pursuing an academic medical career can be singularly rewarding on a personal level. The opportunity to make a lasting impact is the ultimate reward of an academic career, whereas personal legacy or namesake is short-lived. Scientific discovery that informs new pathogenesis, diagnosis and treatment for the diseases that our patients suffer from is the true reward of academic medicine and is worthy of a life-long pursuit.

Wherever the art of medicine is loved, there is also a love of humanity.

Hippocrates

Moderator

Mei-Hsuan Lee

AFFILIATION / INSTITUTION
Institute of Clinical Medicine, National Yang Ming Chiao Tung University (NYCU)

POSITION
Distinguished Professor
Deputy Dean of Research and Development

BRIEF INTRODUCTION

Dr. Mei-Hsuan Lee is an epidemiologist whose research integrates advanced epidemiological methodologies with emerging technologies to investigate the complex interactions between host factors, viral infections, and cancer development. She earned her Ph.D. in 2010 and has been a National Yang Ming Chiao Tung University (NYCU) faculty member since 2012.

Dr. Lee's primary research focuses on liver cancer and biliary tract cancers, with additional contributions to the study of other malignancies. In recent years, her work has expanded to address metabolic dysfunction-associated steatotic liver disease (MASLD)—a condition of growing global prevalence and clinical relevance, particularly in the post-hepatitis era. Her research leverages large-scale population-based datasets, national health registries, and biobank resources to identify risk factors, build risk stratification tools, and inform disease prevention strategies.

Dr. Lee is positioned at the forefront of translational epidemiological research with expertise in study design, statistical modeling, and real-world data analysis. She has authored more than 150 peer-reviewed publications, which have garnered over 11,500 citations (H-index: 45; i10-index: 111), and her work appears in top-tier journals. Committed to interdisciplinary collaboration, Dr. Lee works closely with clinicians, biostatisticians, and molecular scientists to validate research findings and explore their applications in clinical and public health settings. Through these collaborative efforts, she aims to contribute to the advancement of cancer epidemiology and support the development of more effective strategies in precision health.

RESEARCH INTERESTS

Hepatobiliary tract diseases, metabolic dysfunction-associated steatotic liver disease (MASLD), genetic epidemiology, and large-scale data analytics for precision medicine

REPRESENTATIVE PUBLICATIONS

1. Chen TI, Chen MH, Yin SC, Lin CJ, Lam TK, Huang CW, Chen YT, Liu XR, Gao YZ, Hsu WL, Chen HY, Yeh TS, Koshiol J, Lee MH#. Association between metabolic syndrome and cholangiocarcinoma risk: a large-scale population-based cohort study. Hepatology. 2025, in press
2. Lee MH#, Chen YT, Huang YH, Lu SN, Yang TH, Yin SC, Yeh ML, Huang CF, Dai CY, Chuang WL, Yu ML, Yang HI, Chen HY, Chen CJ. Chronic viral hepatitis B and C outweigh MASLD in the associated risk of cirrhosis and HCC. Clin Gastrol Hepatol, 2024; 22 (6): 1275-1285.
3. Chen YT, Chen TI, Yang TH, Yin SC, Lu SN, Liu XR, Gao YZ, Lin CJ, Huang CW, Huang JF, Yeh ML, Huang CF, Dai CY, Chuang WL, Yang HI, Yu ML, Lee MH#. Long-term risks for cirrhosis and hepatocellular carcinoma across steatotic liver disease subtypes. Am J Gastrol, 2024; 119 (11): 2241-2250.
4. Huang YH, Chan C, Lee HW, Huang C, Chen YJ, Liu PC, Lu SN, Chuang WL, Huang JF, Yu ML, Koshiol J, Lee MH#. Influence of nonalcoholic fatty liver disease with elevated liver enzyme levels on risk of cirrhosis and hepatocellular carcinoma. Clinical Gastrol Hepatol, 2023; 21 (4): 960-969
5. Liao SF, Koshiol J, Huang YH, Jackson SS, Huang YH, Chan C, Huang C, Liu PC, Chen YJ, Hsieh R, Huang JB, Lu SN, Chen CJ, Shen CY, Lee MH#. Postdiagnosis aspirin use associated with biliary tract cancer-specific mortality in a large nationwide cohort. Hepatology, 2021; 74 (4): 1994-2006.

Speaker

Hayato Hikita

AFFILIATION / INSTITUTION

Graduate School of Medicine The University of Osaka

POSITION

Associate professor

BRIEF INTRODUCTION

2001	M.D., Osaka University School of Medicine
2001-2007	Residency, Osaka University Hospital & Osaka-Minami Medical Center
2007-2010	Graduate student, Dept. of Gastroenterology and Hepatology, Osaka University, Graduate School of Medicine
2010	Ph.D. in Medical Science, Osaka University
2010-2012	Postdoctoral Fellow, Osaka University Hospital
2012-2022	Assistant Professor, Dept. of Gastroenterology and Hepatology, Osaka University, Graduate School of Medicine
2022-present	Associate Professor, Dept. of Gastroenterology and Hepatology, Osaka University, Graduate School of Medicine

Board-certified in Internal Medicine, Gastroenterology, Hepatology, and Endoscopy

Associate Editor: Hepatology Research, Journal of Gastroenterology

RESEARCH INTERESTS

- Elucidation of the mechanisms of hepatocyte cell death and its role in the progression of liver diseases
- Dissecting intercellular communication within the liver microenvironment during liver fibrosis, hepatocarcinogenesis, and tumor progression
- Real-world data analysis of liver diseases using multicenter cohorts
- Development of novel disease-related biomarkers in liver diseases

REPRESENTATIVE PUBLICATIONS

1. Kudo S, Hikita H, Takehara T, et al. Collaborative orchestration of BH3-only proteins governs Bak/Bax-dependent hepatocyte apoptosis under antiapoptotic protein-deficiency in mice. Cell Death Differ. 2025 in press
2. Kumazaki S, Hikita H, Takehara T, et al. Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis. Aliment Pharmacol Ther. 2024 Aug;60(3):327-339.
3. Makino Y, Hikita H, Takehara T, et al. Constitutive Activation of the Tumor Suppressor p53 in Hepatocytes Paradoxically Promotes Non-Cell Autonomous Liver Carcinogenesis. Cancer Res. 2022 Aug 16;82(16):2860-2873.
4. Myojin Y, Hikita H, Takehara T, et al. Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination. Aliment Pharmacol Ther. 2022 Feb;55(4):422-433.
5. Myojin Y, Hikita H, Takehara T, et al. Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 Production. Gastroenterology. 2021 Apr;160(5):1741-1754.e16.

Cohort, Case-control, and clinical trials: Designing studies for high-quality real-world evidence

Hayato Hikita

Clinical research encompasses a range of study designs, including cohort studies, case-control studies, and randomized controlled trials (RCTs). Among these, RCTs are considered the gold standard for evaluating interventions and are subject to the most rigorous regulatory oversight due to their direct involvement with patient care. In contrast, cohort and case-control studies—both categorized as observational research—are generally not governed by the same level of legal regulation. However, as these studies increasingly inform clinical guidelines and healthcare policy, the need for robust quality management and assurance has become just as critical.

In recent years, several key developments have transformed the environment in which registry-based and multicenter collaborative studies are conducted. These include the widespread adoption of web conferencing platforms, the advancement of electronic data capture (EDC) systems, and growing initiatives to leverage existing healthcare databases. These infrastructural changes have significantly improved the feasibility and scalability of observational research.

In designing such studies, researchers must pay close attention to defining the target population, selecting appropriate follow-up durations, and determining adequate sample sizes to ensure statistical validity. Ethical considerations—such as obtaining informed consent, safeguarding personal data, and complying with national ethical standards like the “Ethical Guidelines for Medical and Health Research Involving Human Subjects”—are also indispensable in maintaining public trust and scientific integrity.

This presentation will provide an overview of clinical study design, highlight recent changes in research infrastructure, and discuss practical and ethical considerations—including data quality management and assurance—in conducting registry and multicenter observational studies that generate reliable and impactful real-world evidence.

Moderator

Seung Up Kim

AFFILIATION / INSTITUTION

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

POSITION

Professor

BRIEF INTRODUCTION

He is a member of Korean Association of the Study of the Liver and Korean Liver Cancer Study Group. He has more than 300 SCI(E) original, peer reviewed publications as primary or corresponding author. He acted as an Editor-in-Chief of Clinical and Molecular Hepatology from 2019 to 2013 and impact factor increased from 4 to 14. He also acts as an Associate Editor of Journal of Gastroenterology and Hepatology and Gut and liver, an Editorial Board of Clinical Gastroenterology and Hepatology, and an Academic Editor of PLoS One, Clinical and Translational Hepatology, and International Journal of Molecular Science. He is an invited referee for more than 20 SCI(E) journals including Lancet Gastroenterology and Hepatology, Gastroenterology, Hepatology, Journal of Hepatology, Gut, etc.

RESEARCH INTERESTS

His major research interests include metabolic associated steatotic liver disease, sarcopenia, viral hepatitis, liver fibrosis, liver cirrhosis, and liver cancer.

REPRESENTATIVE PUBLICATIONS

1. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.
   Lin H, Lee HW, Yip TC, Tsochatzis E, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GB, Chan WK, Gallego-Durán R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castéra L, Lai M, Harrison SA, Fournier-Poizat C, Wong GL, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, de Saint-Loup M, Llop E, Teh KK, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MS, Canivet CM, Romero-Gomez M, Kim SU, Wong VW; VCTE-Prognosis Study Group.JAMA. 2024 Apr 16;331(15):1287-1297. doi: 10.1001/jama.2024.1447.
2. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease.
   Yip TC, Lee HW, Lin H, Tsochatzis E, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GB, Chan WK, Gallego-Durán R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castéra L, Lai M, Fournier-Poizat C, Wong GL, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, de Saint-Loup M, Llop E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MS, Canivet CM, Romero-Gomez M, Kim SU, Wong VW.J Hepatol. 2025 Jan 23:S0168-8278(25)00021-2. doi: 10.1016/j.jhep.2025.01.014.
3. AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment.
   Lin H, Cheuk-Fung Yip T, Lee HW, Meng X, Che-To Lai J, Ahn SH, Pang W, Lai-Hung Wong G, Zeng L, Wai-Sun Wong V, de Lédinghen V, Kim SU.J Hepatol. 2025 Mar;82(3):456-463. doi: 10.1016/j.jhep.2024.09.020.
4. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
   Chun HS, Papatheodoridis GV, Lee M, Lee HA, Kim YH, Kim SH, Oh YS, Park SJ, Kim J, Lee HA, Kim HY, Kim TH, Yoon EL, Jun DW, Ahn SH, Sypsa V, Yurdaydin C, Lampertico P, Calleja JL, Janssen H, Dalekos GN, Goulis J, Berg T, Buti M, Kim SU, Kim YJ.J Hepatol. 2024 Jan;80(1):20-30. doi: 10.1016/j.jhep.2023.09.011
5. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
   Lee HH, Lee HA, Kim EJ, Kim HY, Kim HC, Ahn SH, Lee H, Kim SU.Gut. 2024 Feb 23;73(3):533-540. doi: 10.1136/gutjnl-2023-331003.

Speaker

Mei-Hsuan Lee

AFFILIATION / INSTITUTION
Institute of Clinical Medicine, National Yang Ming Chiao Tung University (NYCU)

POSITION
Distinguished Professor
Deputy Dean of Research and Development

BRIEF INTRODUCTION

Dr. Mei-Hsuan Lee is an epidemiologist whose research integrates advanced epidemiological methodologies with emerging technologies to investigate the complex interactions between host factors, viral infections, and cancer development. She earned her Ph.D. in 2010 and has been a National Yang Ming Chiao Tung University (NYCU) faculty member since 2012.

Dr. Lee's primary research focuses on liver cancer and biliary tract cancers, with additional contributions to the study of other malignancies. In recent years, her work has expanded to address metabolic dysfunction-associated steatotic liver disease (MASLD)—a condition of growing global prevalence and clinical relevance, particularly in the post-hepatitis era. Her research leverages large-scale population-based datasets, national health registries, and biobank resources to identify risk factors, build risk stratification tools, and inform disease prevention strategies.

Dr. Lee is positioned at the forefront of translational epidemiological research with expertise in study design, statistical modeling, and real-world data analysis. She has authored more than 150 peer-reviewed publications, which have garnered over 11,500 citations (H-index: 45; i10-index: 111), and her work appears in top-tier journals. Committed to interdisciplinary collaboration, Dr. Lee works closely with clinicians, biostatisticians, and molecular scientists to validate research findings and explore their applications in clinical and public health settings. Through these collaborative efforts, she aims to contribute to the advancement of cancer epidemiology and support the development of more effective strategies in precision health.

RESEARCH INTERESTS

Hepatobiliary tract diseases, metabolic dysfunction-associated steatotic liver disease (MASLD), genetic epidemiology, and large-scale data analytics for precision medicine

REPRESENTATIVE PUBLICATIONS

1. Chen TI, Chen MH, Yin SC, Lin CJ, Lam TK, Huang CW, Chen YT, Liu XR, Gao YZ, Hsu WL, Chen HY, Yeh TS, Koshiol J, Lee MH#. Association between metabolic syndrome and cholangiocarcinoma risk: a large-scale population-based cohort study. Hepatology. 2025, in press
2. Lee MH#, Chen YT, Huang YH, Lu SN, Yang TH, Yin SC, Yeh ML, Huang CF, Dai CY, Chuang WL, Yu ML, Yang HI, Chen HY, Chen CJ. Chronic viral hepatitis B and C outweigh MASLD in the associated risk of cirrhosis and HCC. Clin Gastrol Hepatol, 2024; 22 (6): 1275-1285.
3. Chen YT, Chen TI, Yang TH, Yin SC, Lu SN, Liu XR, Gao YZ, Lin CJ, Huang CW, Huang JF, Yeh ML, Huang CF, Dai CY, Chuang WL, Yang HI, Yu ML, Lee MH#. Long-term risks for cirrhosis and hepatocellular carcinoma across steatotic liver disease subtypes. Am J Gastrol, 2024; 119 (11): 2241-2250.
4. Huang YH, Chan C, Lee HW, Huang C, Chen YJ, Liu PC, Lu SN, Chuang WL, Huang JF, Yu ML, Koshiol J, Lee MH#. Influence of nonalcoholic fatty liver disease with elevated liver enzyme levels on risk of cirrhosis and hepatocellular carcinoma. Clinical Gastrol Hepatol, 2023; 21 (4): 960-969
5. Liao SF, Koshiol J, Huang YH, Jackson SS, Huang YH, Chan C, Huang C, Liu PC, Chen YJ, Hsieh R, Huang JB, Lu SN, Chen CJ, Shen CY, Lee MH#. Postdiagnosis aspirin use associated with biliary tract cancer-specific mortality in a large nationwide cohort. Hepatology, 2021; 74 (4): 1994-2006.

Statistics for non-statisticians: Bridging clinical insight with AI-enhanced learning

Mei-Hsuan Lee

In the era of evidence-based medicine and artificial intelligence (AI), statistical literacy has become a core competency for clinical physicians. Yet many clinicians continue to feel overwhelmed by statistical terminology or disconnected from the analytical approaches used in clinical research. This lecture is designed to bridge that gap by offering a practical and intuitive introduction to essential statistical concepts, reinforced through real-world clinical applications and the integration of AI-powered tools to support ongoing learning and decision-making.

The session begins with a refresher of core statistical topics—such as measures of central tendency and variability —that provide the basis for summarizing and interpreting clinical data. Key concepts like data types, data distributions, and graphical displays are discussed to build familiarity with how data are organized and visualized. The lecture then moves into inferential statistics, covering confidence intervals, p-values, and the principles underlying study designs, including case-control and cohort studies. To support more advanced data interpretation, the session also introduces regression models and diagnostic accuracy metrics, helping participants build confidence in interpreting the statistical results frequently encountered in research papers and clinical guidelines.

A unique feature of this lecture is the integration of cutting-edge AI tools that serve as intelligent companions before or during clinical data analysis. ChatGPT is introduced as a conversational assistant that can clarify statistical concepts, interpret research findings, translate technical language into plain English, and guide the selection of appropriate statistical tests. Perplexity.ai is demonstrated as a real-time, citation-backed search engine that delivers concise, referenced answers—ideal for refining clinical questions and staying current with the literature. Additional AI tools are briefly showcased to highlight their utility in literature synthesis, research planning, and paper comprehension.

Throughout the session, participants will learn how to craft effective prompts, observe real-time demonstrations, and receive a curated set of recommended AI resources. By the end of the lecture, clinicians will be better equipped to understand and apply statistical methods and will be empowered to use AI tools for clinical reasoning, research design, and lifelong learning.

Mentor

Tatsuya Kanto

Group 1: Viral Hepatitis

AFFILIATION / INSTITUTION
The Research Center for Hepatitis and Immunology, Japan Institute for Health Security (JIHS)

POSITION
Director General

BRIEF INTRODUCTION
Tatsuya Kanto is a researcher and hepatologist/physician with expertise in immunology in liver diseases. He got PhD degree at Osaka University and worked as a research associate for dendritic cell biology at the University of Pittsburgh, USA, from 1998 to 2001. He worked as an Associate Professor at Osaka University from 2003 to 2013 and moved to the National Center for Global Health and Medicine (NCGM). His current position is Director General at the Research Center for Hepatitis and Immunology, Japan Institute for Health Security (JIHS).
He has been working with the Ministry of Health, Labor, and Welfare to promote the Hepatitis Action Plan in Japan. His field of interest is the exploration of the pathogenesis of liver disease for the development of immune-based therapy against viral hepatitis, liver cirrhosis, and cancer. He has published more than 260 papers and invited review articles in peer-reviewed journals, such as Hepatology, Journal of Hepatology, Immunity, Journal of Immunology and Gastroenterology.

RESEARCH INTERESTS
- Immunopathogenesis of viral hepatitis, MASLD/MASH, and liver cancer
- Development of immune modulators for the treatment of chronic HBV infection
- Establishment of therapeutic strategy for congestive liver disease, such as FALD
- Promotion of hepatitis countermeasures in Japan

REPRESENTATIVE PUBLICATIONS
1. Mino M, Kakazu E, Sano A, Tsuruoka M, Matsubara H, Kakisaka K, Kogure T, Sekine K, Aoki Y, Imamura M, Matsuda M, Yamazoe T, Mori T, Yoshio S, Inoue J, Masamune A, Kanto T. Comprehensive analysis of peripheral blood free amino acids in MASLD: the impact of glycine-serine-threonine metabolism. Amino Acids. 2024 Dec 24;57(1):3. doi: 10.1007/s00726-024-03433-2.PMID: 39718621
2. Kogiso T, Tokuhara D, Ohfuji S, Tanaka A, Kanto T. Evaluation of diagnostic criteria for mild-to-advanced stages of Fontan-associated liver disease: A nationwide epidemiological survey in Japan. Hepatol Res 2024 Nov 27. doi: 10.1111/hepr.14141. Online ahead of print.
3. Mori T, Yoshio S, Kakazu E, Kanto T. Active role of the immune system in metabolic dysfunction-associated steatotic liver disease. Gastroenterol Rep (Oxf). 2024 Oct 15;12:goae089. doi: 10.1093/gastro/goae089. eCollection 2024.PMID: 39411101
4. Shigeno S, Kodama T, Murai K, Motooka D, Fukushima A, Nishio A, Hikita H, Tatsumi T, Okamoto T, Kanto T, Takehara T. Intrahepatic exhausted antiviral immunity in immunocompetent mouse model of chronic hepatitis B. Cell Mol Gastroenterol Hepatol. 2024 Sep 28:101412. doi: 10.1016/j.jcmgh.2024.101412. Online ahead of print.PMID: 39349249
5. Takeuchi Y, Nozawa A, Yukimoto A, Kitsuka M, Tateishi R, Kioke K, Okano K, Kanto T. Integrated policy of medical expense subsidies and clinical registry for patients with liver cancer and decompensated cirrhosis in Japan. Hepatol Res. 2024 Jun 15. doi: 10.1111/hepr.14085. Online ahead of print.PMID: 38877867

Mentor

Wen-Juei Jeng

Group 1: Viral Hepatitis

AFFILIATION / INSTITUTION

Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou.

College of Medicine, Chang Gung University

POSITION

Professor; Deputy director of clinical trial center, CGMH, Linkou

BRIEF INTRODUCTION

Dr. Rachel Wen-Juei Jeng obtained her M.D. degree from National Yang-Ming University in Taiwan from 1998 to 2005. She also received her PhD training from the same university from 2012 to 2022. After completing her internal medicine residency and gastroenterology fellowship training at the Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital (CGMH) – Linkou Branch, Taiwan, she became an attending physician in Hepatology in 2010. She currently serves as a Professor in the College of Medicine, Chang Gung University, and as a Physician Scientist at CGMH. Furthermore, she serves as the Deputy Director of the Clinical Trial Center at CGMH.

Dr. Jeng's research interests primarily lie in viral hepatitis, specifically HBV management, finite HBV treatment, clinical trials of new drugs, and clinical/translational hepatology. She is an active member of TASL, EASL, and AASLD and has contributed to the peer-review process for numerous top international journals. She also serves on the editorial board of Hepatology Communication, as an Associate Editor for the Journal of Hepatology (effective October 2024), and as a Fellow of AASLD.

RESEARCH INTERESTS

Chronic hepatitis B natural history and management, clinical and translational research, clinical trials

REPRESENTATIVE PUBLICATIONS

1. Jeng WJ, Chien RN, Chen YC et al. Hepatocellular carcinoma reduced, HBsAg loss increased and survival improved after finite therapy in hepatitis B patients with cirrhosis. Hepatology 2024 Mar 1;79(3):690-703
2. Liu YC, Jeng WJ, Peng CW, Chien RN, Liaw YF. Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Aliment Pharmacol Ther. 2024 Mar;59(6):762-773. (Corresponding author)
3. Jeng WJ, Papatheodoridis G, Lok AS. Hepatitis B Infection. Lancet 2023; 401(10381):1039-52
4. Liu YC, Jeng WJ, Peng CW, Chien RN, Liaw YF. The Role of Off-Therapy Viral Kinetics in the Timing and Severity of Flares in Hepatitis B e Antigen-Negative Patients. Clin Gastroenterol Hepatol. 2023 Jun;21(6):1533-1541.e11. (Co-first author)
5. Peng CW, Jeng WJ*, Yang HI, Liu YC, Chien RN, Liaw YF. A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: An observational study. J Gastroenterol Hepatol. 2022 Nov; 37(11):2164-2172 (*Corresponding)

YI

Yuki Tahata

Group 1: Viral Hepatitis

AFFILIATION / INSTITUTION
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine

POSITION
Assistant professor

BRIEF INTRODUCTION
University: 2002-2008; MD, Osaka City University Faculty of Medicine,
2014-2018; PhD in Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
Residency: 2008-2009; Resident, Osaka General Medical Center, Osaka, Japan
Fellowship:
2009-2012; Clinical Fellow in Gastroenterology and Hepatology, Osaka General Medical Center, Osaka, Japan
2012-2020; Clinical Fellow in Gastroenterology and Hepatology, Osaka University Hospital, Osaka, Japan
2020-Present; Assistant professor, Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine

I have been involved in multicenter clinical studies on liver disease. My research has focused on identifying risk factors for HCC after SVR in patients with HCV, as well as evaluating the efficacy of DAA treatment for decompensated cirrhosis due to HCV. Moving forward, I am committed to continuing clinical research in the field of liver diseases. I believe that my experience at EALA will be invaluable for my future career. Thank you for your consideration.

RESEARCH INTERESTS
Clinical study in liver disease, including:
Viral hepatitis: HCV (post-SVR management, HCV elimination, and management of PWID), HBV (risk factors for HCC after NA therapy, novel treatments).
SLD: Risk factors for liver-related and non-liver-related events, new treatments.

REPRESENTATIVE PUBLICATIONS

1. Tahata Y, et al. Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapy. Hepatol Res. 2024.
2. Tahata Y, et al. Posttreatment liver function but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus. J Gastroenterol. 2023 Dec;58(12):1211-1221.
3. Tahata Y, et al. Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol. 2022 Feb;57(2):120-132.
4. Tahata Y, et al. Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals. Aliment Pharmacol Ther. 2021 Nov;54(10):1340-1349.
5. Tahata Y, et al. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol. 2021 Jan;56(1):67-77.

YI



Kazuya Okushin

Group 1: Viral Hepatitis

AFFILIATION / INSTITUTION
Department of Infection Control and Prevention/The University of Tokyo Hospital

POSITION
Project Lecturer

BRIEF INTRODUCTION
Kazuya Okushin, M.D., Ph.D. graduated from Nagoya University School of Medicine in Japan in 2008.
He completed his residency in internal medicine at Toranomon Hospital and a clinical fellowship in gastroenterology and hepatology at JR Tokyo General Hospital.
He received his Ph.D. in medicine from the Graduate School of Medicine, The University of Tokyo in 2016.
Since 2017, He has been a faculty member of The University of Tokyo.
He is working as a hepatologist in the Department of Gastroenterology, and also serves as a member of the infection control team for The University of Tokyo hospital.

RESEARCH INTERESTS
His area of special interest is the epidemiology of a wide range of liver diseases, including viral hepatitis, steatotic liver disease, cirrhosis, and hepatocellular carcinoma. He has analyzed various datasets, including national data on acute viral hepatitis and several nationwide databases on viral hepatitis, liver cancer, and cirrhosis.
He has conducted epidemiological surveys to determine the true incidence of acute viral hepatitis for the elimination of viral hepatitis in Japan (Ref1). He is now focusing on regional differences in the incidence and characteristics of patients with acute viral hepatitis. He is also involved in the development of a nationwide registry of primary liver cancer and decompensated cirrhosis in Japan (Refs2 and 4). He has demonstrated the real-world management and prognosis of advanced liver diseases in Japan.

He also conducts basic research to elucidate the pathogenesis of steatotic liver diseases, focusing on bile acid metabolism. He first demonstrated that hepatic expression of bile salt export pump (BSEP), a main export transporter of bile acid in the liver, showed a significant negative correlation with disease progression of MASLD in human liver samples (Ref5). He has been involved in experimental studies using BSEP knockout mice.

REPRESENTATIVE PUBLICATIONS

1. Okushin K, et al. Real-world trends in acute viral hepatitis in Japan: A nationwide questionnaire-based survey. Hepatology Research 2025, 55(3), 301-308.
2. Okushin K, et al. Comparable outcomes among etiologies in early-stage hepatocellular carcinoma: Analysis of a nationwide registry in Japan. 2025, 55(4), 556-566.
3. Okushin K, et al. Ursodeoxycholic acid for coronavirus disease 2019 prevention. J Intern Med. 2024, 295(1), 106-109.
4. Okushin K, et al. Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). J Gastroenterol. 2022, 57(8), 587-597.
5. Okushin K, et al. The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease. J Gastroenterol. 2016, 51(8), 808-18.

YI

Jeong-Ju Yoo

Group 1: Viral Hepatitis

AFFILIATION / INSTITUTION

Department of Internal Medicine Soonchunhyang University Bucheon Hospital

POSITION

Associate Professor

BRIEF INTRODUCTION

I am Jeong-Ju Yoo, currently an Associate Professor in the Department of Hepatology, Internal Medicine, at Soonchunhyang University College of Medicine, Soonchunhyang University Bucheon Hospital, Korea.

I completed my medical education at Seoul National University College of Medicine, earning my M.D. degree in 2009, followed by a Master's (2015) and Ph.D. (2019) in Internal Medicine from the same institution.

My professional career includes medical internship (2009-2010) and residency in Internal Medicine (2010-2014) at Seoul National University Hospital. I was also a Research Fellow at the Department of Internal Medicine and Liver Research Institute at Seoul National University College of Medicine (2014-2015). In 2016, I joined Soonchunhyang University Bucheon Hospital as an Assistant Professor, and I have been serving as an Associate Professor since 2024.

My clinical and research interests primarily focus on hepatology, particularly viral hepatitis, liver cirrhosis, hepatocellular carcinoma, liver fibrosis, and metabolic liver diseases. I have published numerous peer-reviewed articles and have received multiple awards for excellence in research and presentations, including Best Presentation Awards at major academic conferences.

Currently, I actively participate in several academic societies, serving on various committees, including the Korean Association for the Study of the Liver, Korean Liver Cancer Association, and Korean Society of Gastroenterology.

RESEARCH INTERESTS

1. Hepatocellular carcinoma (HCC): Pathogenesis, therapeutic strategies, and prognostic factors 2.Metabolic liver diseases: Non-alcoholic fatty liver disease (NAFLD) and metabolic-associated fatty liver disease (MAFLD) 3.Liver fibrosis and portal hypertension: Non-invasive diagnostic methods and clinical management 4.Clinical applications of ultrasound and elastography in liver disease 5.Prognostic modeling and biomarkers for chronic liver diseases 6.Viral hepatitis management and antiviral therapies 7.Microbiome studies in liver cirrhosis and related complications

REPRESENTATIVE PUBLICATIONS

1. Jeong-Ju Yoo et al. "Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex." Journal of Hepatology, 2019;70:847-854.
2. Jeong-Ju Yoo et al. "Validation of the Texas Hepatocellular Carcinoma Risk Index Predictive Model for Hepatocellular Carcinoma in Asian Cohort." Clinical Gastroenterology and Hepatology, 2024 Mar 13; S1542-3565(24)00255-6.
3. Jeong-Ju Yoo et al. "Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis." Hepatology International, 2023 Apr 26.
4. Jeong-Ju Yoo et al. "Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation." Liver International, 2015 Dec;35(12):2530-2536.
5. Jeong-Ju Yoo et al. "Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase." Clinical and Molecular Hepatology, 2023 Apr;29(2):482-495.

YI

Won-Mook Choi

Group 1: Viral Hepatitis

AFFILIATION / INSTITUTION
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine

POSITION
Assistant Professor

EDUCATION
Doctor of Medicine, Seoul National University College of Medicine, Seoul, South Korea
Mar 2004 - Feb 2010
M.S. in Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
Advisor: Prof. Jung-Hwan Yoon
Mar 2013 - Feb 2015
Ph.D. in Medical Science and Engineering, Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea
Advisor: Prof. Won-Il Jeong
Mar 2015 - Feb 2019

POSTGRADUATE TRAINING
Mar 2010 - Feb 2011	Medical Internship, Seoul National University Hospital, Seoul, South Korea
Mar 2011 - Feb 2015	Residency, Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Mar 2019 - Feb 2021	Clinical Fellow, Gastroenterology and Hepatology, Department of Gastroenterology, Asan Medical Center / University of Ulsan College of Medicine, Seoul, South Korea

PROFESSIONAL APPOINTMENTS
Mar 2021 - Feb 2022	Clinical Assistant Professor, Department of Gastroenterology, Asan Medical Center / University of Ulsan College of Medicine, Seoul, South Korea
Mar 2022 - Present	Assistant Professor, Department of Gastroenterology,Asan Medical Center / University of Ulsan College of Medicine, Seoul, South Korea

REPRESENTATIVE PUBLICATIONS

1. Chung SW, Um HJ, Choi WM (corresponding), Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee HC. Tenofovir is associated with a better prognosis than entecavir for hepatitis B virus-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2025 Feb;23(2):300-309.e9.
2. Choi WM, Kim GA, Choi J, Choi GH, Lee YB, Sinn DH, Lim YS. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B. Gut. 2024 Mar 7;73(4):649-658.
3. Choi WM (co-first), Yip TC, Wong GL, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Cant H, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin JW, Yang YH, Lim YS. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. J Hepatol. 2023 Mar;78(3):534-542.
4. Choi WM, Kim GA, Choi J, Han S, Lim YS. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B. J Clin Invest. 2022 May 16;132(10):e154833.
5. Choi WM, Kim HH, Kim MH, Cinar R, Yi HS, Eun HS, Kim SH, Choi YJ, Lee YS, Kim SY, Seo W, Lee JH, Shim YR, Kim YE, Yang K, Ryu T, Hwang JH, Lee CH, Choi HS, Gao B, Kim W, Kim SK, Kunos G, Jeong WI. Glutamate Signaling in Hepatic Stellate Cells Drives Alcoholic Steatosis. Cell Metab. 2019 Nov 5;30(5):877-889.e7.

YI

Yen-Chun Liu

Group 1: Viral Hepatitis

AFFILIATION / INSTITUTION
Chang Gung Memorial Hospital, Linkou branch, Taiwan

POSITION
Assistant Professor

EDUCATION

1. M.D. College of Medicine, Chang Gung University, Taiwan (2007-2014)
2. Resident, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou branch, Taiwan (2014-2018)
3. Gastroenterology fellowship, Chang Gung Memorial Hospital, Linkou branch, ´Taiwan (2018-2020)
4. Attending physician, Department of Hepatology and Gastroenterology, Chang Gung Memorial Hospital, Linkou branch, Taiwan (2020-current)
5. Doctor of Philosophy, Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taiwan (2022-current)

RESEARCH INTERESTS
Clinical phenotypes and immunology in chronic hepatitis.

REPRESENTATIVE PUBLICATIONS

1. Liu YC, Jeng WJ, Peng CW, Chien RN, Liaw YF. Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals. Alimentary Pharmacology & Therapeutics 2024; 59(6): 762-773.
2. Liu YC, Jeng WJ, Peng CW, Chien RN, Liaw YF. The role of off-therapy viral kinetics in the timing and severity of flares in hepatitis B e antigen-negative patients. Clinical Gastroenterology and Hepatology 2023;21(6):1533-1541.
3. Liu YC, Cheng YT, Chen YC, Hsieh YC, Jeng WJ, Lin CY, Chien RN, Tai DI, Sheen IS. Comparing predictability of non-invasive tools for hepatocellular carcinoma in treated chronic hepatitis C patients. Digestive Diseases and Sciences 2022;1-10.
4. Liu YC, Jeng WJ, Peng CW, Chien RN, Liaw YF. Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapy. Liver International 2022; 42: 551-560.
5. Liu YC, Jeng WJ, Chen CH. Keystone to secure safety after stopping nucleos (t) ide analogue therapy in chronic hepatitis B patients. Clinical Gastroenterology and Hepatology 2022; 20(8): 1890-1891.

YI



Hsin-Ju Tsai

Group 1: Viral Hepatitis

AFFILIATION / INSTITUTION
Division of Gastroenterology and Hepatology, Taichung Veterans General Hospital

POSITION
Attending physician

EDUCATION
2002-2009 M.D. School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
2019-2024 Ph.D. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.

PROFESSIONAL EXPERIENCE
2010-2013 Resident, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
2013-2015 Chief Resident, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
2015-2016 Fellow, Division of Gastroenterology and Hepatology,Taichung Veterans General Hospital, Taichung, Taiwan.
2016-2021 Hospitalist, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
2022- Attending Physician, Division of Gastroenterology and Hepatology, Taichung Veterans General Hospital, Taichung, Taiwan.

RESEARCH INTERESTS
The impact of nucleos(t)ide analogue for Hepatitis B on renal function.
Safety issues of nucleos(t)ide analogue in renal transplant recipients with chronic hepatitis B.

REPRESENTATIVE PUBLICATIONS
1. Tsai HJ, Chuang YW, Lee SW, Wu CY, Yeh HZ, Lee TY. Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients. Aliment Pharmacol Ther. 2018;47:1673–1681.
2. Tsai HJ, Chuang YW, Yang SS, Chang YZ, Chang HR, Lee TY. Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease. J Viral Hepat. 2021 Nov;28(11):1579-1586.
3. Tsai HJ, Wu MJ, Chen CH, Yang SS, Huang YH, Chang YZ, Chang HR, Lee TY. Risk Stratification for Hepatitis B Virus Reactivation in Kidney Transplant Recipients With Resolved HBV Infection. Transpl Int. 2023 Apr 13;36:11122.

Mentor

Takumi Kawaguchi

Group 2: MASLD

AFFILIATION / INSTITUTION
Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine

POSITION
Professor

EDUCATION/EMPLOYMENT HISTORY
1995, MD. Degree from Kurume University School of Medicine
1999, Ph.D. Degree in Kurume University Graduate School of Medicine
2000, Research Fellow, University of Texas, Southwestern Medical Center, Texas, USA.
2012, Assistant Prof. Div. of Gastroenterology, Dept. of Medicine, Kurume University School of Medicine
2022, Professor and Chairman, Div. of Gastroenterology, Dept. of Medicine, Kurume Univ. School of Med.

COMMITTEE / MEMBER
1. The Japan Society of Hepatology, International Committee Member
2. Evidence-Based Clinical Practice Guidelines for MASLD 2025, Committee Member
3. Clinical and Molecular Hepatology, Editorial Board Member
4. The Global MASH Council, Member

RESEARCH INTERESTS
1. Nutritional therapy for liver cirrhosis
2. Exercise and anti-diabetic therapy for MASLD

REPRESENTATIVE PUBLICATIONS
1. Suzuki H, Fujiwara N, Singal AG, Baumert TF, Chung RT, Kawaguchi T, Hoshida Y. Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic. Hepatology. 2025 in press.
2. Hashida R, Nakano D, Kawaguchi M, Younossi ZM, Kawaguchi T. Changing from NAFLD to MASLD: The implications for health-related quality of life data. J Hepatol. 2024;80:e249-e251.
3. Nakano M, Kawaguchi M, Kawaguchi T. Almost identical values of various non-invasive indexes for hepatic fibrosis and steatosis between NAFLD and MASLD in Asia. J Hepatol. 2024;80:e155-e157.
4. Suzuki H, Tanaka T, Yamaguchi S, Miwa K, Kawaguchi T. Changing from NAFLD to MASLD: Similar prognosis of unresectable extrahepatic gastrointestinal cancer under chemotherapy between NAFLD and MASLD. J Hepatol. 2024;80:e150-e151.
5. Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7:388-390.

Mentor

Jee-Fu Huang

Group 2: MASLD

AFFILIATION / INSTITUTION
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital
Center for Metabolic Disorders and Obesity, Kaohsiung Medical University

POSITION
Professor

BRIEF INTRODUCTION
Professor Huang was graduated from Kaohsiung Medical University in 1989 and received his Ph.D. from the Graduate Institute of Medicine, Kaohsiung Medical University in 2011. He is currently 1) Clinical Professor of Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; 2) Director, Hepatitis Center, Kaohsiung Medical University Hospital and Kaohsiung Medical University; 3) Professor, College of Medicine and the Graduate Institute of Clinical Medicine, Kaohsiung Medical University; 4) Member of Board, Taiwan Liver Research Foundation; and 5) Director, Department of Medical Research, Kaohsiung Medical University Hospital. Prof. Huang's main research interests include basic and clinical research of viral hepatitis, fatty liver disease, and liver metabolism. He serves as Associate Editor of Kaohsiung Journal of Medical Science and academic editor of many international journals. He has also served as the chair of Institutional Review Board of Kaohsiung Medical University Hospital. He has published more than 250 peer-reviewed articles in the past decade and has conducted many clinical trials as principal investigator or sub-investigator. He consistently makes his efforts in constructing epidemiological works for viral hepatitis elimination, particularly in the endemic and under-resourced areas in Taiwan. He has also conducted many collaborative projects with the international allies against liver diseases in our global community.

RESEARCH INTERESTS
viral hepatitis, disease control, fatty liver disease, hepatoendocrinology, and clinical trial.

REPRESENTATIVE PUBLICATIONS

1. Huang JF, Chang TJ, Yeh ML, Shen FC, Tai CM, Chen JF, Huang YH, Hsu CY, Cheng PN, Lin CL, Hung CH, Chen CC, Lee MH, Lee CC, Lin CW, Liu SC, Yang HI, Chien RN, Kuo CS, Peng CY, Chang ML, Huang CF, Yang YS, Yang HC, Lin HC, Ou HY, Liu CJ, Tseng CH, Kao JH, Chuang WL, Huang CN, Chen PJ, Wang CY*, Yu ML*. 2024. Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus. Hepatol Commun. 2024 Oct 30;8(11):e0571. PMID: 39470335.
2. Yeh ML, Huang JF*, Dai CY, Huang CF, Yu ML, Chuang WL. 2024. Metabolic dysfunction-associated steatotic liver disease and diabetes: the cross-talk between hepatologist and diabetologist. Expert Rev Gastroenterol Hepatol. 2024 Aug;18(8):431-439. PMID: 39099428.
3. Huang CF, Dai CY, Lin YH, Wang CW, Jang TY, Liang PC, Lin TC, Tsai PC, Wei YJ, Yeh ML, Hsieh MY, Huang CK, Huang JF*, Chuang WL, Yu ML*. 2024. Dynamic change of MASLD in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan. Clin Mol Hepatol. 2024 Jul 29. PMID: 39069721.
4. Huang CF, Yeh ML, Dai CY, Huang JF*, Chuang WL, Yu ML*. 2024. Chronic hepatitis C related steatotic liver disease is more than "miscellaneous steatotic liver disease". Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00430-0. PMID: 38729391.
5. Huang CF, Liang PC, Tsai PC, Wei YJ, Huang CI, Wang CW, Jang TY, Yeh ML, Hsu PY, Hsieh MY, Lin YH, Dai CY, Chuang WL, Huang JF*, Yu ML*. 2024. The interplay of metabolic dysfunction-associated fatty liver disease and viral hepatitis on liver disease severity: A large community-based study in a viral endemic area. J Gastroenterol Hepatol. 2024 Jan;39(1):193-201. PMID: 37731071.

YI

Norihiro Imai

Group 2: MASLD

AFFILIATION / INSTITUTION

Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine

POSITION

Assistant Professor

ACADEMIC BACKGROUND

2005: Department of Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Doctoral Course: 2016: Department of Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

PROFESSIONAL APPOINTMENT

From 2009 to 2012: Fellow, Department of Hepatology, Toranomon Hospital
(Research topic: Interventional treatment of hepatocellular carcinoma)
From 2017 to 2020: Postdoctoral Associate, Department of Medicine, Weill Cornell Medical College
(Research topic: NAFLD rodent models at the laboratory of Professor David E. Cohen)
From 2020 to present: Assistant Professor, Department of Endoscopy, Nagoya University Hospital
(Research topic: alcohol-associated liver disease and MASLD in rodent models)

RESEARCH INTERESTS

Interventional treatment of hepatocellular carcinoma
Pathophysiology of steatotic liver disease

REPRESENTATIVE PUBLICATIONS

1. Imai N, Yamamoto T, Mizuno K, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Kawashima H. A Proposal for a Simple Subclassification of Advanced Hepatocellular Carcinoma in Systemic Treatment. Cancers (Basel). 2024 Nov 12;16(22):3797
2. Imai N, Ohsaki Y, Cheng J, Zhang J, Mizuno F, Tanaka T, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishigami M, Wake H, Kawashima H. Distinct features of two lipid droplets types in cell nuclei from patients with liver diseases. Sci Rep. 2023 Apr 26;13(1):6851.
3. Imai N, Ishigami M, Oie Y, Kumagai M, Inukai Y, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Kawashima H. Effectiveness of Porous Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Solitary Hepatocellular Carcinoma. Anticancer Res. 2022 Aug;42(8):3947-3951.
4. Imai N, Nicholls HT, Alves-Bezerra M, Li Y, Ivanova AA, Ortlund EA, Cohen DE. Up-regulation of thioesterase superfamily member 2 in skeletal muscle promotes hepatic steatosis and insulin resistance in mice. Hepatology. 2022 Jan;75(1):154-169.
5. Imai N, Cohen DE. Trimming the Fat: Acetyl-CoA Carboxylase Inhibition for the Management of NAFLD. Hepatology. 2018 Dec;68(6):2062-2065.

YI

Han Ah Lee

Group 2: MASLD

AFFILIATION / INSTITUTION
Chung-Ang University

POSITION
Assistant professor

BRIEF INTRODUCTION

2018: Ph.D. in Korea University
2016-2017: Clinical Fellow in Hepatology (Korea University Anam Hospital)
2018-2020: Clinical Assistant Professor in Hepatology (Korea University Anam Hospital)
2021: Clinical Assistant Professor in Hepatology (Inje University Sanggye Baik Hospital)
2022-2023: Clinical Assistant Professor in Hepatology (Ewha Womans University Mokdong Hospital)
2024: Assistant Professor in Hepatology (Chung-Ang University Seoul Hospital)

RESEARCH INTERESTS

Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatitis B virus, Hepatocellular carcinoma

REPRESENTATIVE PUBLICATIONS

1. A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B. (J Hepatol. 2025)
2. Effects of Intermittent Calorie Restriction in Nondiabetic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. (Clin Gastroenterol Hepatol. 2025)
3. Metabolic Dysfunction-Associated Steatotic Liver Disease and Risk of Cardiovascular Disease: A Nationwide Cohort Study (Gut. 2024)
4. Identification of patients with favorable prognosis after resection in intermediate-stage hepatocellular carcinoma. (Int J Surg. 2024)
5. Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-analysis. (Clin Mol Hepatol. 2024)

YI

Young-Sun Lee

Group 2: MASLD

AFFILIATION / INSTITUTION

Department of Internal Medicine, Division of Gastroenterology and Hepatology, Guro Hospital, Korea University College of Medicine

POSITION

Assistant professor

ACADEMIC QUALIFICATIONS

2000.3 - 2006.2 M.D. in Korea University Medical College
2008.9 - 2010.8 M.S., Department of Medicine in Korea university medical college
2011.2 - 2015.2 Ph.D., Graduate School of Medical Science & Engineering, KAIST, Korea

PROFESSIONAL EXPERIENCE

2006.3 - 2007.2 Internship training in Korea University Medical Center
2007.3 - 2011.2 Resident training of Internal Medicine in Korea University Medical Center
2015.3 - 2017.2 Clinical Instructor in Department of Internal Medicine, Division of Gastroenterology and Hepatology, Guro hospital, Korea University College of Medicine
2017.2 - 2018.8 Clinical Associate Professor in Department of Internal Medicine, Divi-sion of Gastroenterology and Hepatology, Guro hospital, Korea Univer-sity College of Medicine
2018.9 - 2021.2 Assistant Professor in Department of Internal Medicine, Division of Gastroenterology and Hepatology, Guro hospital, Korea University College of Medicine
2021.3 - present Associate Professor in Department of Internal Medicine, Division of Gastroenterology and Hepatology, Guro hospital, Korea University College of Medicine

RESEARCH INTERESTS

MASLD, EV, Noninvasive biomarker, Liver immunology, Hepatocellular carcinoma

REPRESENTATIVE PUBLICATIONS

1. Lee YS, Seki E. In Vivo and in Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations. Cell Mol Gastroenterol Hepatol 2023.
2. Park SH, Lee EK, Yim J, Lee YS et al. Exosomes: Nomenclature, Isolation, and Biological Roles in Liver Diseases. Biomol Ther (Seoul) 2023;31:253-63.
3. Lee YS, Lee JE, Yi HS, et al. MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatol Int 2022;16:316-24.
4. Lee HA, Chang Y, Sung PS, Lee YS et al. Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. Clin Mol Hepatol 2022;28:425-72.
5. Kim TH, Lee Y, Lee YS, et al. Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease. Sci Rep 2021;11:14639.

YI

Shang-Chin Huang

Group 2: MASLD

AFFILIATION / INSTITUTION
National Taiwan University / National Taiwan University Hospital / National Taiwan University Hospital Bei-Hu br.

POSITION
Attending Physician

CURRENT POSITION
Attending physician, Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan
Attending physician, Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Attending physician, Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan
Clinical lecturer, National Taiwan University College of Medicine, Taipei, Taiwan

EDUCATION
2007-2014: M.D., College of Medicine, National Yang-Ming University, Taipei, Taiwan
2021-now: Ph.D. student, Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

ACADEMIC HONOR
2022 APASL STC on HCC: Young Investigator Award
2022 APASL STC on HCC: Outstanding Abstract Award
2022 Liver Disease Prevention & Treatment Research Foundation: Liver Disease Research Award
2022 Taiwan Digestive Disease Week (TDDW): Young Investigator Award
2023 APASL Annual Meeting: Young Investigator Award
2023 APASL Annual Meeting: The Best Poster of YI
2023 TDDW: Young Investigator Award
2024 APASL STC on MAFLD: Young Investigator Award
2024 Taiwan Association for the Study of the Liver (TASL): Distinguished Young Scholar Award
2024 APAGE Research Programme Award (Co-investigator)
2025 APASL Rising Star Award

RESEARCH INTERESTS
1.Metabolic dysfunction-associated steatotic liver disease (MASLD) 2.Hepatitis B virus (HBV) 3.The interaction between MASLD and HBV

REPRESENTATIVE PUBLICATIONS
1. SC Huang, TH Su, TC Tseng et al. All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease. J Hepatol. 2025 (in press): S0168-8278(24)02763-6.
2. SC Huang, TH Su, TC Tseng et al. Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B. Am J Gastroenterol. 2025 Feb 1;120(2):401-409.
3. SC Huang, TH Su, TC Tseng et al. Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion. Clin Gastroenterol Hepatol. 2024 Mar;22(3):581-590.e6.
4. SC Huang, TH Su, TC Tseng et al. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B. Hepatol Int. 2023 Oct;17(5):1139-1149.
5. SC Huang, CJ Liu. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives. Clin Mol Hepatol. 2023 Apr;29(2):320-331

YI

Kai-Chi Chang

Group 2: MASLD

AFFILIATION / INSTITUTION
Attending physician, Department of Pediatrics, National Taiwan University Hospital

POSITION
Assistant Professor

EDUCATION
09/2001-06/2008 M.D. College of Medicine, National Taiwan University
09/2013-01/2016 Master Graduate Institute of Clinical Medicine, National Taiwan University
09/2017-01/2024 Ph.D. Graduate Institute of Clinical Medicine, National Taiwan University
07/2008-06/2011 Resident Department of Pediatrics, National Taiwan University Hospital
07/2011-06/2013 Fellow Pediatric Gastroenterology, Hepatology, and Nutrition, National Taiwan University Hospital

RESEARCH INTERESTS
Viral hepatitis
Pediatric liver transplantation
Gut microbiota
Obesity in children and metabolic dysfunction associated fatty liver disease

REPRESENTATIVE PUBLICATIONS
1. Chang KC, Chang MH, Chen HL, Cheng FW, Wu JF, Su WJ, Hsu HY, Ni YH. Survey of hepatitis B virus infection status after 35 years of universal vaccination implementation in Taiwan. Liver Int. 2024 Aug;44(8):2054-2062.
2. Chang KC, Chua HH, Chen YH, Tsuei DJ, Lee MH, Chiang CL, Jeng YM, Wu JF, Chen HL, Hsu HY, Ni YH, Chang MH. Hepatitis B virus X gene impacts on the innate immunity and immune-tolerant phase in chronic hepatitis B virus infection. Liver Int. 2022 Oct;42(10):2154-2166.
3. Liao FM, Chang KC, Wu JF, Chen HL, Ni YH, Chang MH. Direct Bilirubin and Risk of Biliary Atresia. Pediatrics. 2022 Jun 1;149(6):e2021053073.
4. Chang KC, Chang MH, Chen HL, Wu JF, Chang CH, Hsu HY, Ni YH. Universal Infant Hepatitis B Virus (HBV) Vaccination for 35 years: moving toward the Eradication of HBV. J Infect Dis. 2021 Aug 7:jiab401.Aug;50(3):306-316.
5. Chang KC, Chang MH, Lee CN, Chang CH, Wu JF, Ni YH, Wen WH, Shyu MK, Lai MW, Chen SM, Hu JJ, Lin HH, Hsu JJ, Mu SC, Lin YC, Liu CJ, Chen DS, Lin LH, Chen HL; Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT study). Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers. Aliment Pharmacol Ther. 2019 Aug;50(3):306-316.

YI

Shih-Chieh Chien

Group 2: MASLD

AFFILIATION / INSTITUTION
Internal Medicine / National Cheng Kung University Hospital

POSITION
Assistant Professor

EDUCATION

2001.8 - 2008.7	Student	School of medicine, Tzu Chi University
2017.9 - present	Ph.D. student	Institute of Clinical Medicine, College of Medicine, National Cheng Kung University
2023.2 - present	Associate Professor	Department internal medicine, National Cheng Kung University Hospital

RESEARCH INTERESTS
1. Metabolic dysfunction associated fatty liver disease
2. Hepatocellular carcinoma
3. Bile acid

REPRESENTATIVE PUBLICATIONS

1. Shih-Chieh Chien, Hung-Chih Chiu, Yen-Cheng Chiu, Karl Paolo O. Dillera, Kuo-Ting Lee, Hung-Wen Tsai, Yau-Sheng Tsai1, Horng-Yih Ou, Pin-Nan Cheng. Clinical Relevancies of Sarcopenic Obesity in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD). Digestive Disease and Science. 2025;70(3):1190-1200. doi: 10.1007/s10620-025-08844-z. (First Author)
2. Pin-Nan Cheng, I-Cher Feng, Jyh-Jou Chen, Hsing-Tao Kuo, Pei-Lun Lee, Ming-Lung Yu, Yen-Cheng Chiu, Hung-Chih Chiu, Shih-Chieh Chien, Pei-Jer Chen, Chun-Jen Liu. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B. Alimentary Pharmacology Therapeutics. 2024 Jan;59(2):230-238. doi: 10.1111/apt.17765.
3. Shih-Chieh Chien, Yih-Jyh Lin, Chun-Te Lee, Yen-Cheng Chiu, Tsung-Ching Chou, Hung-Chih Chiu 1, Hung-Wen Tsai, Che-Min Su, Tsung-Han Yang, Hsueh-Chien Chiang, Wei-Chu Tsai, Kai-Chun Yang, Pin-Nan Cheng. Higher risk of tumor recurrence in NASH-related hepatocellular carcinoma following curative resection. Viruses. 2022;14:2427. (First Author)
4. Hsueh-Chien Chiang, Shih-Chieh Chien, Yih-Jyh Lin (2022, Feb). Pleural effusion with gastric ulcer. Gastroenterology. 162(2) E16-19.
5. Shih-Chieh Chien, Chiung-Yu Chen, Pin-Nan Cheng, Yi-Shan Liu, Hsiu-Chi Cheng, Chiao-Hsiung Chuang, Ting-Tsung Chang, Hong-Chi Chiu, Yih-Jyh Lin, Yen-Cheng Chiu. Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study. Liver cancer. 2019;8:186-202. (First Author).

Mentor



Moon Young Kim

Group 3: Cirrhosis

AFFILIATION / INSTITUTION

Yonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea

POSITION

Professor

BRIEF INTRODUCTION

I am a professor currently in the Department of Internal Medicine, Yonsei University Wonju College of Medicine. I have been provided medical treatments and researched mainly on gastroenterology and hepatology for over 15 years. My specialized areas are liver sinusoidal endothelial cell pathophysiology and related hepatic fibrosis and I have worked on preclinical studies on the mechanism of endothelial dysfunction/portal hypertension. Recently I have focused on cell therapy by using stem cells for hepatic fibrosis and angiogenesis. I am also interested in non-invasive diagnosis of hepatic fibrosis or portal hypertension using contrast-enhanced ultrasonography. From the clinical research point, the impact of gut microbiota on cirrhosis/portal hypertension and the application of treatment is one of my main research projects.

RESEARCH INTERESTS

Assessment and Treatment of Portal hypertension and Cirrhosis

Stem cell therapy for hepatic regeneration and anti-fibrosis

The cross talk between sinusoidal remodeling, angiogenesis and hepatic fibrosis

Noninvasive evaluation of hepatic fibrosis and portal hypertension using contrast enhanced ultrasonography

REPRESENTATIVE PUBLICATIONS

1. Kang SH, Lee M, Kim MY, Lee JH, Jun BG, Kim TS, Choi DH, Suk KT, Kim YD, Cheon GJ, Kim DJ, Baik SK. The longitudinal outcomes of applying non-selective beta-blockers in portal hypertension: real-world multicenter study. Hepatol Int. 2021 Apr;15(2):424-436.
2. Kang SH, Jeong WK, Baik SK, Cha SH, Kim MY. Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. J Cachexia Sarcopenia Muscle. 2018 Oct;9(5):860-870.
3. Lim YL, Kim MY, Jang YO, Baik SK, Kwon SO. Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study. Gut Liver. 2017 Sep 15;11(5):702-710
4. Kim MY, Cho MY, Baik SK, Jeong PH, Suk KT, Jang YO, et al. Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - A randomized open-label controlled study. Liver Int. 2012 Jul;32(6):977-87
5. Kim MY, Cho MY, Baik SK, Park HJ, Jeon HK, Im CK, Won CS, Kim JW, Kim HS, Kwon SO, Eom MS, Cha SH, Kim YJ, Chang SJ, Lee SS. Histological subclassification of cirrhosis using Laennec fibrosis scoring system correlates with clinical stages and grades of portal hypertension in patients with cirrhosis. J hepatol 2011 Nov;55:1004-1009

Mentor

Kuei-Chuan Lee

Group 3: Cirrhosis

AFFILIATION / INSTITUTION
Taipei Veterans General Hospital

POSITION
Professor

EDUCATION
Kuei Chuan Lee (MD, PhD) obtains his MD degree in Faculty of Medicine, School of Medicine, National Yang-Ming University (1994-2001) and Ph.D degree in institute of Clinical Medicine, School of Medicine, National Yang-Ming University (2010-2014). He received his postdoctoral training in Schnabl lab in University of California, San Diego (2015-2016).
Kuei Chuan Lee (MD, PhD) is a Professor of the Internal Medicine in National Yang Ming Chiao Tung University (NYCU), an attending physician in Taipei Veterans General Hospital and the Chief of cirrhosis and portal hypertension therapeutic and research center.

RESEARCH INTERESTS
His research field of interest surrounds fatty liver disease, liver fibrosis, liver cirrhosis, portal hypertension, gut microbiota and gastrointestinal endoscopy. He has published more than 90 SCI papers. In recent years, some papers are published in Arch Gerontol Geriatr. 2023, Clin Mol Hepatol. 2023, JHEP Rep. 2022, FASEB J. 2022, Mol Nutr Food Res. 2021, Cell Mol Gastroenterol Hepatol. 2021, Clin Sci (Lond). 2020, Lab Invest. 2019, Am J Physiol Gastrointest Liver Physiol. 2019. He has been a reviewer for journals such as Journal of hepatology, Liver international, Hepatology international, Journal of endocrinology, Journal of physiology, Journal of nanoparticle, Journal of Gastroenterology and Hepatology, Plos one, Scientific report.

REPRESENTATIVE PUBLICATIONS

1. Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol. 2023 Jan;29(1):77-98.
2. Sarcopenia-related gut microbial changes are associated with the risk of complications in people with cirrhosis. Lee PC*, Lee KC*, Yang TC, Lu HS, Cheng TY, Chen YJ, Chiou JJ, Huang CW, Yang UC, Chia-Hui Tan E, Chou SH, Kuo YL, Schnabl B, Huang YH, Hou MC. JHEP Rep. 2022 Oct 29;5(1):100619. *: equal contribution
3. Lee PC, Hsieh YC, Huo TI, Yang UC, Lin CH, Li CP, Huang YH, Hou MC, Lin HC, Lee KC*. Active Vitamin D Treatment Attenuated Bacterial Translocation via Improving Intestinal Barriers in Cirrhotic Rats. Mol Nutr Food Res. 2021 Feb;65(3):e2000937. *: Correspondence
4. Hsieh YC, Lee KC*, Lei HJ, Lan KH, Huo TI, Lin YT, Chan CC, Schnabl B, Huang YH, Hou MC, Lin HC. (Pro)renin Receptor Knockdown Attenuates Liver Fibrosis Through Inactivation of ERK/TGF-β1/SMAD3 Pathway. Cell Mol Gastroenterol Hepatol. 2021;12(3):813-838. *: correspondence
5. Lee KC, Lin HC, Huang YH, Hung SC. Allo-transplantation of mesenchymal stem cells attenuates hepatic injury through IL1Ra dependent macrophage switch in a mouse model of liver disease. J Hepatol. 2015 Dec;63(6):1405-12.

YI



Takao Miwa

Group 3: Cirrhosis

AFFILIATION / INSTITUTION
Gifu University Hospital, Gifu, Japan

POSITION
Medical Doctor

BRIEF INTRODUCTION

Takao Miwa is a gastroenterologist and hepatologist whose academic and clinical career is centered at the Department of Gastroenterology/Internal Medicine at Gifu University Hospital. He earned his M.D. in 2015 and completed his Ph.D. in 2024, specializing in hepatology and nutrition. His professional career includes roles as both a physician and a researcher, with significant contributions in areas such as liver cirrhosis, nutrition, hepatic encephalopathy, sarcopenia, frailty, and steatotic liver disease. As a lead author, his publications have advanced research on zinc deficiency in patients with covert hepatic encephalopathy, the association between handgrip strength decline and hepatic encephalopathy, a simplified screening model for covert hepatic encephalopathy, the effectiveness of levocarnitine administration in patients with cirrhosis, and papers on new international standards for malnutrition, sarcopenia, and prognosis. These papers have been cited in guidelines by the European Association for the Study of the Liver and the Japan Society of Hepatology, contributing to the clinical management of liver cirrhosis. Additionally, his recent publications include a multicenter study on acute kidney injury and its association with amino acid imbalance in the Japanese population, and a nationwide survey on the current management and future perspectives of covert hepatic encephalopathy in Japan. The significance of his work is underscored by awards such as the JSGE-UEG Rising Stars award and multiple young investigator awards. Takao Miwa also serves on the editorial committee for the "Evidence-based Clinical Practice Guidelines for Liver Cirrhosis," highlighting his commitment to advancing medical standards and practices.

RESEARCH INTERESTS

Liver cirrhosis, Nutrition, Hepatic Encephalopathy, Sarcopenia, Frailty, Steatotic liver disease

REPRESENTATIVE PUBLICATIONS

1. Miwa T, Tsuruoka M, Ueda H, et al. Current management and future perspectives of covert hepatic encephalopathy in Japan: a nationwide survey. J Gastroenterol. 2025. doi: 10.1007/s00535-025-02232-0.
2. Miwa T, Suda G, Tateishi R, et al. Cachexia is an independent predictor of mortality in patients with cirrhosis. Hepatol Res. 2025. doi: 10.1111/hepr.14183.
3. Miwa T, Utakata Y, Hanai T, et al Acute kidney injury development is associated with mortality in Japanese patients with cirrhosis: impact of amino acid imbalance. J Gastroenterol. 2024;59:849-857.
4. Miwa T, Hanai T, Nishimura K, et al. Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality in patients with chronic liver disease. Hepatol Res. 2022;52:928-936.
5. Miwa T, Hanai T, Nishimura K, et al. Handgrip strength stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis. JPEN J Parenter Enteral Nutr. 2022;46:858-866.

YI

Soon Sun Kim

Group 3: Cirrhosis

AFFILIATION / INSTITUTION
Ajou University School of Medicine

POSITION
Professor

EDUCATION
1999-2005, Doctor of Medicine, Ajou University School of Medicine
2007-2010, Master in Medicine, Ajou University School of Medicine
2010-2013, Ph.D degree in Medicine, Ajou University School of Medicine

PROFESSIONAL EXPERIENCE
2006-2010, Resident, Ajou University Hospital
2010-2012, Clinical fellow, Ajou University Hospital
2012-2016, Clinical Assistant professor, Ajou University Hospital
2016-2020, Assistant professor, Ajou University Hospital
2020-2025, Associate professor, Ajou University Hospital
2025-, Professor, Ajou University Hospital

RESEARCH INTERESTS
Translational Research, Biomarker, HCC, Microbiome, Big-data, MASLD

REPRESENTATIVE PUBLICATIONS

1. Son JA, Weon JH, Baek GO, et al. Circulating small extracellular vesicle-derived splicing factor 3b subunit 4 as a non-invasive diagnostic biomarker of early hepatocellular carcinoma. J Exp Clin Cancer Res. 2023;42(1):288. Published 2023 Oct 30. doi:10.1186/s13046-023-02867-y
2. Ahn HR, Baek GO, Yoon MG, et al. Hypomethylation-mediated upregulation of the WASF2 promoter region correlates with poor clinical outcomes in hepatocellular carcinoma. J Exp Clin Cancer Res. 2022;41(1):158. Published 2022 Apr 28. doi:10.1186/s13046-022-02365-7
3. Kim SS, Baek GO, Son JA, et al. Early detection of hepatocellular carcinoma via liquid biopsy: panel of small extracellular vesicle-derived long noncoding RNAs identified as markers. Mol Oncol. 2021;15(10):2715-2731. doi:10.1002/1878-0261.13049
4. Kim SS, Eun JW, Cho HJ, et al. Microbiome as a potential diagnostic and predictive biomarker in severe alcoholic hepatitis. Aliment Pharmacol Ther. 2021;53(4):540-551. doi:10.1111/apt.16200
5. Kim SS, Baek GO, Ahn HR, et al. Serum small extracellular vesicle-derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma. Mol Oncol. 2020;14(10):2646-2659. doi:10.1002/1878-0261.12745

YI

Tyng-Yuan Jang

Group 3: Cirrhosis

AFFILIATION / INSTITUTION
Kaohsiung Medical University

POSITION
Attending Physician, Department of Hepatobiliary of internal medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
Department of Internal Medicine, Pingtung Hospital, Ministry of Health and Welfare, Ping-Tung, Taiwan
Clinical Assistant Professor, Kaohsiung Medical University

BRIEF INTRODUCTION
I earned my Bachelor's degree from national cheng kung university in Medicine in 2012. Now I am studying PHD of environmental science at KMU. Then I worked as Residence at Kaohsiung Medical University Hospital from 2012. While performing chief resident, the performance was well-being and got first place in the gastroenterology specialty exam. The research at fellow period was mainly focus on the epidemiological data on hepatitis in individuals with frequent blood transfusions.
I committed to research on hepatitis and liver cancer. Most of his current works focus on hepatitis B, C, D and liver cancer. Currently, there are about 40 SCI articles published by the first author. There are three articles stating that hepatitis D can still cause hepatitis flare, HCC, etc. while taking oral antiviral drugs for hepatitis B. Two articles describe that uric acid and blood sugar will improve after liver C treatment. Other epidemiological data are described, such as Pingtung hepatitis C and hepatitis in patients with frequent blood transfusions. There is also an article describing the predictive factors of liver cancer in patients with hepatitis B who use oral antiviral drugs. The performance of hepatitis B, C and liver index under COVID-19 infection has also been described. Committed to integrating academic and clinical services to serve more patients.
My primary research interest is hepatitis. In particular, I focus my groundbreaking research on hepatitis and air pollution. Specifically, I am pioneering research in the relationship between air pollution and chronic liver disease. Significantly, my research is viewed as so essential to the progress of my field that I have published 40 articles in domestic and international journals, including globally recognized prestigious journals such as liver international and Alimentary Pharmacology & Therapeutics, which are widely circulated.

RESEARCH INTERESTS
1.Hepatitis 2.HCC 3.Air pollution

REPRESENTATIVE PUBLICATIONS

1. Tyng-Yuan Jang et al Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues(ALIMENTARY PHARMACOLOGY & THERAPEUTICS 2025;2025(0):1-9; IF: 6.6, Journal Ranking: 21, Number of Journals of this Field: 354, Ranking: 5.93%))
2. Tyng-Yuan Jang et al Role of air pollution in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues (Liver International accepted; 2023, IF: 6.0, Gastroenterology & Hepatology: 20/143=13.6%)
3. Tyng-Yuan Jang et al Air pollution as a potential risk factor for hepatocellular carcinoma in Taiwanese patients after adjusting for chronic viral hepatitis. JOURNAL OF THE CHINESE MEDICAL ASSOCIATION : JCMA - JOURNAL OF THE CHINESE MEDICAL ASSOCIATION 2024;87(3):287-291 (2023, IF: 1.9, Journal Ranking: 105, Number of Journals of this Field: 329, Ranking: 31.8%)
4. Tyng-Yuan Jang et al Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY - JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 2024;39(6):1190-1197 (2023, IF: 3.7, Journal Ranking: 40, Number of Journals of this Field: 143, Ranking: 28.6%)
5. Tyng-Yuan Jang et al Hepatitis B surface antigen loss in chronic hepatitis B patients with low-viral-load JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY - JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 2024;39(6):1190-1197 (2023, IF: 3.7, Journal Ranking: 40, Number of Journals of this Field: 143, Ranking: 28.6%)

YI

Yun-Cheng Hsieh

Group 3: Cirrhosis

AFFILIATION / INSTITUTION
Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans GeneralHospital

POSITION
Attending physician

EDUCATION
2008 M.D. National Yang-Ming University
2021 Ph.D. Institute of Pharmacology, National Yang Ming Chiao Tung University
2014 Attending physician, Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital
2021 Assistant Professor, School of Medicine, National Yang Ming Chiao Tung University
Aug 2019 Visiting Scholar, Boramae Medical Center, Seoul, Korea
July 2023-June 2024 Post-doc fellowship, Beth Israel Deaconess Medical Center, MA

RESEARCH INTERESTS
Basic, translational and clinical research of MASLD

REPRESENTATIVE PUBLICATIONS

1. Hsieh YC, Joo SK, Koo BK, Lin HC, Lee DH, Chang MS, Park JH, So YH, Kim W. Myosteatosis, but not Sarcopenia, Predisposes NAFLD Subjects to Early Steatohepatitis and Fibrosis Progression. Clin Gastroenterol Hepatol. 2023 Feb;21(2):388-397.
2. Hsieh YC, Wu PS, Lin YT, Huang YH, Hou MC, Lee KC, and Lin HC. (Pro)renin receptor inhibition attenuated liver steatosis, inflammation and fibrosis in mice with steatohepatitis. FASEB J. 2022 Oct;36(10):e22526.
3. Hsieh YC, Lee KC, Lei HJ, Lan KH, Huo TI, Lin YT, Chan CC, Schnabl B, Huang YH, Hou MC, Lin HC. (Pro)renin Receptor Knockdown Attenuates Liver Fibrosis Through Inactivation of ERK/TGF-β1/SMAD3 Pathway. Cell Mol Gastroenterol Hepatol. 2021;12(3):813-838
4. Hsieh YC, Lee KC, Wu PS, Huo TI, Huang YH, Hou MC, Lin HC. Eritoran Attenuates Hepatic Inflammation and Fibrosis in Mice with Chronic Liver Injury. Cells. 2021 Jun 21;10(6):1562.
5. Hsieh YC, Lee KC, Wang YW, Yang YY, Hou MC, Huo TI, Lin HC. Correlation and prognostic accuracy between noninvasive liver fibrosis markers and portal pressure in cirrhosis: Role of ALBI score. PLoS One. 2018 Dec 12;13(12):e0208903.

YI



Yu-Ju Wei

Group 3: Cirrhosis

AFFILIATION / INSTITUTION
Division of Hepatobiliary, Department of Internal Medicine Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

POSITION
Attending physician

EDUCATION
2020-	PhD student, Institute of Biomedical Sciences, National Sun Yat-sen University, Taiwan
2007-2012	Department of Post Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

PROFESSIONAL TRAINING
2012-2013	Post graduate year Resident, Chi-Mei Medical Center, Tainan, Taiwan
2013-2016	Resident, Department of Internal medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
2016-2017	Fellowship, Division of Geriatrics and Gerontology, Department of Internal medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
2017/09	Harvard medical school Beth Israel Deaconess Medical Center Geriatric Medicine Observership Program
2017-2019	Fellowship, Division of Hepatobiliary, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

RESEARCH INTERESTS
1.HCV and post SVR outcome among hemodialysis patients 2.Chronic liver disease and sarcopenia 3.Fatty liver disease 4.Aging and the liver disease

REPRESENTATIVE PUBLICATIONS
1. Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan-the Formosa-Like Group.. J Viral Hepatology. 2021, May
Wei YJ, Hsu PY, Lee JJ, Niu SW, Huang JC, Hsu CT, Jang TY, Yeh ML, HuangCI, Liang PC, Lin YH, Hsieh MY, Hsieh MH, Chen SC, Dai CY, Lin ZY, Chen SC, Huang JF, Chang JM, Hwang SJ, Chuang WL, Huang CF, Chiu YW, Yu ML.
2. Establishment of an outreach, grouping healthcare system to achieve microelimi-nation of HCV for uremic patients in haemodialysis centres (ERASE-C).. Gut. 2020, Dec.
Yu ML*, Huang CF*, Wei YJ*, Lin WY, Lin YH, Hsu PY, Hsu CT, Liu TW, Lee JJ, Niu SW, Huang JC, Hung TS, Yeh ML, Huang CI, Liang PC, Hsien MY, Chen SC, Huang JF, Chang JM, Chiu YW, Dai CY, Hwang SJ, Chuang WL; FORMOSA-LIKE investigators.
3. The influence of integrated geriatric outpatient clinics on the health care utilization of older people.
BMC Geriatr. (2020, Oct).

Mentor



Do Young Kim

Group 4: HCC

AFFILIATION / INSTITUTION
Yonsei University College of Medicine

POSITION
Professor

BRIEF INTRODUCTION
Do Young Kim is now a professor of Internal Medicine at Yonsei University College of Medicine, Seoul, Korea, and a hepatologist in the Severance Hospital where he has been a faculty member since 2007. He graduated Yonsei University at 1996, and completed training course in Severance Hospital from 1996 to 2001. He studied proteomics and microRNA in hepatocellular carcinoma (HCC) at Fred Hutchinson Cancer Research Center as a research associate between 2011 and 2012.

RESEARCH INTERESTS
Hepatocellular carcinoma
Biomarker

REPRESENTATIVE PUBLICATIONS
1. Lee HJ, Kim MJ, Kim DY, et al. [Co-corresponding author] Non-contrast resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance: A randomized, single-center trial. Gastroenterology [Online ahead of print].
2. Choi M, …, Kim DY, Choi GH. [Co-corresponding author] Is liver resection still required for patients who have predictive factors for complete pathological necrosis after downstaging treatments of locally advanced hepatocellular carcinoma? Eur J Surg Oncol 2025;51(1):109349
3. Chon YE, …, Kim DY. [Corresponding author] Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study. Clin Mol Hepatol 2024;30:345-359.
4. Kim GM, Kim DY, Who JY, et al. Outcome of transarterial radioembolization in the treatment of hepatocellular carcinoma: Glass versus resin microsphere. Cardiovasc Intervent Radiol 2024;47:1210-1221.
5. Cho KJ, …, Kim DY. [Corresponding author] YAP/TAZ suppress drug penetration into hepatocellular carcinoma via stromal activation. Hepatology 2021;74:2605-2621.

Mentor

Yi-Hsiang Huang

Group 4: HCC

AFFILIATION / INSTITUTION

Department of Medical Research, Taipei Vet-erans General Hospital, Taipei, Taiwan.

Institute of Clinical Medicine, College of Medi-cine, National Yang Ming Chiao Tung Univer-sity, Taipei, Taiwan

POSITION

Director / Chair Professor

BRIEF INTRODUCTION

Prof. Yi-Hsiang Huang is the President (2023-2027) of Taiwan Liver Cancer Association (TLCA), and the Director of Medical Research at the Taipei Veterans General Hospital (since 2025 Jan). He is also the Chair Professor for the Institute of Clinical Medicine at the National Yang Ming Chiao Tung University. Completing his medical and PhD training at National Yang Ming University, he furthered his training as a research fellow at the Vaccine Branch of National Cancer Institute, National Institute of Health, USA from 2006 to 2007. Prof. Huang became a full professor at the Institute of Clinical Medicine, NYCU in 2011, and the Chair Professor at NYCU since Aug. 2022.

Prof. Huang has served as the council member of Asia-Pacific Primary Liver Cancer Expert Association (APPLE) since Jul. 2023; the executive committee member of Taiwan Association for the Study of the Liver (TASL) since Sep. 2023; the secretary general of the Chinese Medical Association (CMA) of Taiwan (2020-2026), the council member of the Taiwan Academy of Tumor Ablation (TATA), the Chairman of the 2025 Asia Pacific Association for the Study of the Liver (APASL) STC Oncology.

RESEARCH INTERESTS

Prof. Huang's study interest is in the virology and immunology of viral hepatitis and HCC, including HBV reactivation related to immunosuppressive and immune checkpoint inhibitors therapy; and HCC treatment across locoregional to systemic therapy.

REPRESENTATIVE PUBLICATIONS

1. Mon HC, Lee PC, Hung YP, Hung YW, Wu CJ, Lee CJ, Chi CT, Lee IC, Hou MC, Huang YH*. Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy. J Hepatol 2025 Jan; 82(1): 51-61 (*corresponding author)
2. Hung YW, Lee IC, Chi CT, Lee RC, Liu CA, Chiu NC, Hwang HE, Chao Y, Hou MC, Huang YH*. Radiologic Patterns Determine the Outcomes of Initial and Subsequent Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer. 2024 Feb;13 (1): 29-40. (*corresponding author)
3. Lee PC, Wu CJ, Hung YW, Lee CJ, Chi CT, Lee IC, Yu-Lun K, Chou SH, Luo JC, Hou MC, Huang YH*. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitors-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2022 Jun;10(6):e004779. (*corresponding author)
4. Chen MH*, Lee IC, Chen MH, Hou MC, Tsai CY, Huang YH*. Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. Annals of Rheumatic Diseases 2021 Nov;80(11):1393–1399. (*corresponding author)
5. Lee IC, Huang JY, Chen TC, Yen CH, Chiu NC, Hwang HE, Huang JG, Liu CA, Chau GY, Lee RC, Hung YP, Chao Y, Ho SY*, Huang YH*. Evolutionary Learning Derived Clinical-Radiomic Models for Predicting Early Recurrence of Hepatocellular Carcinoma After Resection. Liver Cancer. 2021 Nov;10(6):572-582 (*corresponding author)

YI

Keisuke Koroki

Group 4: HCC

AFFILIATION / INSTITUTION
Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan

POSITION
Project Assistant Professor

BRIEF INTRODUCTION
I am a physician-scientist and board-certified gastroenterologist specializing in hepatology. I graduated from the Hamamatsu University School of Medicine in 2012 and obtained my Ph.D. in Medicine from Chiba University Graduate School of Medicine in 2020. My doctoral research focused on clinical trial design for hepatocellular carcinoma in the era of systemic therapies. Currently, I am affiliated with the Department of Gastroenterology at Chiba University Hospital, where I am engaged in both patient care and clinical research. As a Project Assistant Professor, I also work at the Liver Disease Consultation Center, providing patients with personalized support, including information on treatment options and public subsidy systems.

My research focuses on hepatocellular carcinoma, particularly the development of combination therapies involving immune checkpoint inhibitors and radiotherapy. I am also actively involved in the application of machine learning and telemedicine to optimize liver disease management. I have conducted complex analyses using multicenter clinical datasets and published several papers on systemic therapy for liver cancer. I have also contributed to numerous physician-initiated clinical trials. I have been recognized with several early-career awards, including the Breakthrough Abstract Award at the American Society of Clinical Oncology (ASCO) in 2024. Going forward, I aim to contribute to the implementation of novel treatment strategies in collaboration with a diverse group of researchers, and to support regional healthcare through the use of AI and ICT-based approaches.

RESEARCH INTERESTS
My research interests focus on hepatocellular carcinoma, especially the synergistic effects of combining systemic therapies with other modalities such as particle beam radiotherapy. I am actively engaged in clinical trial design and real-world data analysis to develop optimal treatment strategies. I also explore the use of machine learning to support personalized medicine. Furthermore, I am interested in how ICT can contribute to equitable access to hepatitis care across regions.

REPRESENTATIVE PUBLICATIONS

1. Koroki K, Ogasawara S, Izai R, et al. Comprehensive Analysis of Radiologic Cancer-Free Status through Various Treatment Approaches in Advanced-Stage Hepatocellular Carcinoma. Liver Cancer. Published online November 13, 2024:1–16.
2. Ogasawara S, Koroki K, Makishima H, et al. Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. BMJ Open. 2022 Apr 8;12(4): e058987.
3. Yoshida R, Koroki K, Makishima H, et al. Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. Case Reports in Oncology. 2021 Jul 15;14(2):1103–1110.
4. Koroki K, Ogasawara S, Ooka Y, et al. Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer. 2021;10(5):473–484.
5. Koroki K, Ogasawara S, Ooka Y, et al. Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer. 2020;9(6):596–612.

YI

Tomoaki Yoh

Group 4: HCC

AFFILIATION / INSTITUTION
Department of Surgery, Kyoto University

POSITION
Assistant Professor

EDUCATION
2002-2008: Student, Doctor of Medicine, Mie University
2008-2010: Resident, Department of Surgery, Saiseikai Izuo Hospital, Osaka, Japan
2010-2014: Fellow, Department of Surgery, Yamatotakada Municipal Hospital, Nara, Japan
2014-2018: Ph.D. Candidate, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2018-2019: Research fellow, Université Paris VII Denis Diderot, Paris, France
2020-2021: Fellow, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2021-present: Assistant Professor, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

RESEARCH INTERESTS
Hepatocellular carcinoma, Intrahepatic Cholangiocarcinoma, Cancer Immunology, Cancer Molecular Biology, Randomized control trial

REPRESENTATIVE PUBLICATIONS

1. Hori Y, Yoh T, Nishino H, et al. Ferroptosis-related gene glutathione peroxidase 4 promotes reprogramming of glucose metabolism via Akt- mTOR axis in intrahepatic cholangiocarcinoma. Carcinogenesis. 2024 Mar 11;45(3):119-130. (Corresponding author)
2. Yoh T, Cauchy F, Soubrane O. Oncological Resection for Liver Malignancies: Can the Laparoscopic Approach Provide Benefits? Ann Surg. 2022 Jan 1;275(1):182-188.
3. Yoh T, Cauchy F, Le Roy B, et al. Prognostic value of lymphadenectomy for long-term outcomes in node-negative intrahepatic cholangiocarcinoma: A multicenter study. Surgery. 2019 Dec;166(6):975-982.
4. Yoh T, Seo S, Taura K, et al. Surgery for Recurrent Hepatocellular Carcinoma: Achieving Long-term Survival. Ann Surg. 2021 Apr 1;273(4):792-799.
5. Yoh T, Hatano E, Kasai Y, et al. Serum Nardilysin, a Surrogate Marker for Epithelial- Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection. Clin Cancer Res. 2019 Jan 15;25(2):619-628.

YI

Soon Kyu Lee

Group 4: HCC

AFFILIATION / INSTITUTION
Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea

POSITION
Associate Professor

BRIEF INTRODUCTION
Prof. Soon Kyu Lee is an associate professor in the Division of Gastroenterology and Hepatology at the Catholic University of Korea. He is actively conducting both basic and clinical research related to hepatocellular carcinoma, transplantation, autoimmune liver disease, hepatitis virus infection, and alcoholic liver disease.

Prof. Soon Kyu Lee graduated from the Catholic University of Korea, College of Medicine with his medical degree in 2011 and completed his internship and residency at the Department of Internal Medicine at The Catholic University of Korea, receiving his Ph.D. in Internal Medicine in 2022.

Prof. Soon Kyu Lee has demonstrated a strong commitment to both basic and clinical research and has received several prestigious honors, including the Young Investigator Award at the Asia-Pacific Primary Liver Cancer Expert (APPLE) Meeting 2023 and recognition as one of the Top 50 Outstanding Achievements (2023) in the Ministry of Education's Academic and Research Support Program, for which he was awarded by the Deputy Prime Minister and Minister of Education of Korea.

RESEARCH INTERESTS
Hepatocellular carcinoma, Liver transplantation, Gut microbiome, Autoimmune liver disease, hepatitis virus infection, and alcoholic liver disease

REPRESENTATIVE PUBLICATIONS
1. Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation, Clinical and Molecular Hepatology (2025) 31:131-146
2. Expansion of effector regulatory T cells in steroid-responders of severe alcohol-associated hepatitis, Liver Transplantation (2024) DOI: 10.1097/LVT.0000000000000378
3. An Early Increase in IL-10 and TNF-α Levels Following Atezolizumab Plus Bevacizumab Treatment Predicts Survival in Advanced Hepatocellular Carcinoma Patients: A Prospective Cohort Study, Cancers (2024), Oct 21;16(20):3543
4. A decrease in functional microbiomes represented as Faecalibacterium affects immune homeostasis in long-term stable liver transplant patients, Gut microbes (2022), 14:1, 2102885
5. Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination, Journal of Hepatology (2022), 77:1207-1230

YI

Yeonjung Ha

Group 4: HCC

AFFILIATION / INSTITUTION
CHA Bundang Medical Center, CHA University

POSITION
Associate Professor

EDUCATION

2003-2009	Inje University College of Medicine, M.D. (summa cum laude)
2009	Internship, Asan Medical Center
2010-2013	Residency, Internal Medicine, Asan Medical Center
2012-2014	University of Ulsan College of Medicine, M.S.
2013	Short-term Training, Prince of Wales Hospital, Hong Kong S.A.R., China
2014-2015	Clinical Fellowship, Gastroenterology, Asan Medical Center
2014-2017	University of Ulsan College of Medicine, Ph.D.
2016-2023	Assistant Professor, Gastroenterology, CHA Bundang Medical Center
2017-2019	Visiting Scientist, Mayo Clinic, United States
2024-	Associate Professor, Gastroenterology, CHA Bundang Medical Center

RESEARCH INTERESTS
Hepatocellular carcinoma
Metabolic dysfunction-associated steatotic liver disease
Predictive modeling

REPRESENTATIVE PUBLICATIONS

1. Ha Y, Lee S, Lim J, et al. A Machine Learning Model to Predict De Novo Hepatocellular Carcinoma Beyond Year 5 of Antiviral Therapy in Patients With Chronic Hepatitis B. Liver Int 2025;45(4):e16139. DOI: 10.1111/liv.16139.
2. Cheon J, Kim H, Kim HS, (…), Ha Y et al. Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma. Ther Adv Med Oncol 2023;15:17588359221148541. DOI: 10.1177/17588359221148541.
3. Ha Y, Lim J, Chon YE, et al. Five-year on-treatment variables-based PPACS model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir-treated patients. Int J Cancer 2023;153(12):2045-2054. DOI: 10.1002/ijc.34704.
4. Yang H, Kang B, Ha Y, et al. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma. JHEP Reports : innovation in hepatology 2023;5(4):100672. DOI: 10.1016/j.jhepr.2023.100672.
5. Ha Y, Kim JH, Cheon J, Jeon GS, Kim C, Chon HJ. Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab. Clin Gastroenterol Hepatol 2023;21(9):2421-2423.e2. DOI: 10.1016/j.cgh.2022.07.035.

YI

Hung-Wei Wang

Group 4: HCC

AFFILIATION / INSTITUTION

Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan

School of Medicine, China Medical University, Taichung, Taiwan

POSITION

Attending Physician, Center for Digestive Medi-cine, Department of Internal Medicine, China Medical University

Assistant Professor, Department of Internal Medicine, China Medical University

EDUCATION

M.D., College of Medicine, Taipei Medical University, Taipei, Taiwan, Sep. 2001 - Jun. 2008

Ph.D. Program in the Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, Sep. 2023-Present

PROFESSIONAL EXPERIENCE

Resident, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Branch, Taiwan, Aug. 2009 - Jun. 2012

Fellow, Division of Gastroenterology & Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taiwan, Jul. 2012 - Jul. 2014

Attending Physician, Division of Gastroenterology & Hepatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Branch, Taiwan, Aug. 2014 - Feb. 2016

Attending Physician, Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Apr. 2016 - Present

Assistant Professor, Department of Internal Medicine, China Medical University, Taichung, Taiwan, Aug. 2020 - Present

RESEARCH INTERESTS

1.Viral hepatitis, hepatocellular carcinoma, risk prediction models 2.Liver fibrosis, noninvasive indices, clinical applications 3.Hepatocellular carcinoma, targeted therapy, immunotherapy, predictive factors 4.Hepatocellular carcinoma, prognostic indicators, real-world data analysis

REPRESENTATIVE PUBLICATIONS

1. Hung-Wei Wang, Cheng-Yuan Peng*, Hsueh-Chou Lai, Wen-Pang Su, Chia-Hsin Lin, Po-Heng Chuang, Sheng-Hung Chen, Ching-Hsiang Chen, Wei-Fan Hsu, Guan-Tarn Huang. New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis. Sci Rep 2017;7:3259.
2. Hung-Wei Wang, Hsueh-Chou Lai, Tsung-Hui Hu, Wen-Pang Su, Sheng-Nan Lu, Chia-Hsin Lin, Chao-Hung Hung, Po-Heng Chuang, Jing-Houng Wang, Mei-Hsuan Lee, Chien-Hung Chen*, Cheng-Yuan Peng*. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy. J Gastroenterol Hepatol 2019;34:442-449.
3. Hung-Wei Wang, Po-Heng Chuang, Wen-Pang Su, Jung-Ta Kao, Wei-Fan Hsu, Chun-Che Lin, Guan-Tarn Huang, Jaw-Town Lin, Hsueh-Chou Lai, Cheng-Yuan Peng*. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2021;13.
4. Wei Teng, Hung-Wei Wang, Shi-Ming Lin*; Diagnosis Group and Systemic Therapy Group of TLCA. Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. Liver Cancer 2024;13:468-486.
5. Hung-Wei Wang, Hsueh-Chou Lai, Wen-Pang Su, Jung-Ta Kao, Wei-Fan Hsu, Hung-Yao Chen, Che-Wei Chang, Guan-Tarn Huang, Cheng-Yuan Peng*. Real-world experience of lenvatinib-based therapy in patients with advanced hepatocellular carcinoma. J Gastrointest Oncol 2024;15:2216-2229.

YI



Shu-Hsien Lin

Group 4: HCC

AFFILIATION / INSTITUTION

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital

POSITION

Attending physician

EDUCATION

2008-2015	Graduated from Chung Shan Medical University, Taiwan
2015-2022	Residency and fellowship of hepato-gastroenterology in CGMH, Kaohsiung
2022-2024	Attending physicians of hepato-gastroenterology in CGMH, Kaohsiung
2024-	Attending physicians of division of Gastroenterology and Hepatology, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital

RESEARCH INTERESTS

Molecular biology of HCC

REPRESENTATIVE PUBLICATIONS

1. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection. J. Pers. Med. 2021 July; 11(8):684.
2. Characteristics and prognosis of patients with large well-differentiated hepatocellular carcinoma who have undergone resection. Am J Surg. 2022 Feb;223(2):339-345.
3. Reappraisal of the Roles of Alpha-Fetoprotein in Hepatocellular Carcinoma Surveillance Using Large-Scale Nationwide Database and Hospital-Based Information. J Formos Med Assoc. 2022 Apr 19:S0929-6646(22)00144-9.
4. Liver Graft MicroRNAs Expression in Different Etiology of Acute Jaundice after Living Donor Liver Transplantation. Biology (Basel) 2022 Aug 17;11(8):1228. doi: 10.3390/biology11081228.
5. Mitochondrial alterations and signatures in hepatocellular carcinoma. Cancer Metastasis Rev. 2025;44(1):34.

Moderator

Tatsuya Kanto

AFFILIATION / INSTITUTION

The Research Center for Hepatitis and Immunology, Japan Institute for Health Security (JIHS)

POSITION

Director General

BRIEF INTRODUCTION

Tatsuya Kanto is a researcher and hepatologist/physician with expertise in immunology in liver diseases. He got PhD degree at Osaka University and worked as a research associate for dendritic cell biology at the University of Pittsburgh, USA, from 1998 to 2001. He worked as an Associate Professor at Osaka University from 2003 to 2013 and moved to the National Center for Global Health and Medicine (NCGM). His current position is Director General at the Research Center for Hepatitis and Immunology, Japan Institute for Health Security (JIHS).

He has been working with the Ministry of Health, Labor, and Welfare to promote the Hepatitis Action Plan in Japan. His field of interest is the exploration of the pathogenesis of liver disease for the development of immune-based therapy against viral hepatitis, liver cirrhosis, and cancer. He has published more than 260 papers and invited review articles in peer-reviewed journals, such as Hepatology, Journal of Hepatology, Immunity, Journal of Immunology and Gastroenterology.

RESEARCH INTERESTS

- Immunopathogenesis of viral hepatitis, MASLD/MASH, and liver cancer
- Development of immune modulators for the treatment of chronic HBV infection
- Establishment of therapeutic strategy for congestive liver disease, such as FALD
- Promotion of hepatitis countermeasures in Japan

REPRESENTATIVE PUBLICATIONS

1. Mino M, Kakazu E, Sano A, Tsuruoka M, Matsubara H, Kakisaka K, Kogure T, Sekine K, Aoki Y, Imamura M, Matsuda M, Yamazoe T, Mori T, Yoshio S, Inoue J, Masamune A, Kanto T. Comprehensive analysis of peripheral blood free amino acids in MASLD: the impact of glycine-serine-threonine metabolism. Amino Acids. 2024 Dec 24;57(1):3. doi: 10.1007/s00726-024-03433-2.PMID: 39718621
2. Kogiso T, Tokuhara D, Ohfuji S, Tanaka A, Kanto T. Evaluation of diagnostic criteria for mild-to-advanced stages of Fontan-associated liver disease: A nationwide epidemiological survey in Japan. Hepatol Res 2024 Nov 27. doi: 10.1111/hepr.14141. Online ahead of print.
3. Mori T, Yoshio S, Kakazu E, Kanto T. Active role of the immune system in metabolic dysfunction-associated steatotic liver disease. Gastroenterol Rep (Oxf). 2024 Oct 15;12:goae089. doi: 10.1093/gastro/goae089. eCollection 2024.PMID: 39411101
4. Shigeno S, Kodama T, Murai K, Motooka D, Fukushima A, Nishio A, Hikita H, Tatsumi T, Okamoto T, Kanto T, Takehara T. Intrahepatic exhausted antiviral immunity in immunocompetent mouse model of chronic hepatitis B. Cell Mol Gastroenterol Hepatol. 2024 Sep 28:101412. doi: 10.1016/j.jcmgh.2024.101412. Online ahead of print.PMID: 39349249
5. Takeuchi Y, Nozawa A, Yukimoto A, Kitsuka M, Tateishi R, Kioke K, Okano K, Kanto T. Integrated policy of medical expense subsidies and clinical registry for patients with liver cancer and decompensated cirrhosis in Japan. Hepatol Res. 2024 Jun 15. doi: 10.1111/hepr.14085. Online ahead of print.PMID: 38877867

Speaker



Wonseok Kang

AFFILIATION / INSTITUTION
Sungkyunkwan University School of Medicine, Samsung Medical Center

POSITION
Associate Professor of Medicine
Chief, Digestive Disease Center

BRIEF INTRODUCTION

Wonseok Kang is an Associate Professor of Medicine at Sungkyunkwan University School of Medicine, and the Chief of Digestive Disease Center at Samsung Medical Center, Seoul, Korea.

He graduated from Yonsei University with his medical degree in 2004 and completed his residency at the Department of Internal Medicine in Severance Hospital in 2009. After completing his clinical training, he pursued a Ph.D. in Medical Science and Engineering at Korea Advanced Institute of Science and Technology (KAIST) in 2013.

Recently, he spent a year as a Visiting Research Scholar at The Jackson Laboratory for Genomic Medicine and Yale School of Medicine in Connecticut, USA. After returning from his sabbatical, he is currently focusing on translational research in the field of hepatology in relation to his clinical practice.

RESEARCH INTERESTS

Hepatocellular carcinoma, immunotherapy, biomarkers

REPRESENTATIVE PUBLICATIONS

1. Molecular landscape of tumor-associated tissue-resident memory T cells in tumor microenvironment of hepatocellular carcinoma. Cell Commun Signal 2025
2. Unraveling the immune-activated tumor microenvironment correlated with clinical response to atezolizumab plus bevacizumab in advanced HCC. JHEP Rep. 2024
3. Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Med 2022

Scientific communication: Presentation skills

Wonseok Kang

Successful research careers are largely dependent on effective scientific communication, particularly for young medical professionals beginning their careers in clinical and translational research. This talk will offer helpful suggestions on how to organize scientific presentations, create effective slides, and confidently deliver information. The basic framework of a scientific discussion, methods for creating understandable and attractive slides, and delivery approaches will be addressed. Common issues including managing presentation anxiety as well as responding to audience questions will also be covered. By the end of this talk, participants will be better prepared to present their research findings effectively and professionally, enhancing both their academic visibility and collaborative opportunities.

Moderator



Su Jong Yu

AFFILIATION / INSTITUTION

Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine

POSITION

Clinical Professor

EDUCATIONAL

Doctor of Medicine, College of Medicine, Dept. of Medicine, Seoul National University (March 1, 1997-February 26, 2001)
Master of Science in Medicine, Graduate School, Seoul National University (March 1, 2004-February 24, 2006)
Doctor of Philosophy in Medical Science, Graduate School, Seoul National University (March 1, 2010-February 24, 2012)

PROFESSIONAL CAREER

Clinical Professor, Department of Internal Medicine & Liver Research Institute, SNU College of Medicine (2011.03-Present)
Visiting Scientist, NCI, NIH (Bethesda, MD, USA) (2016-2018)
Director of the Planning Committee, KASL (2023.12-Present)
Academy Affairs Director, KLCA (2022.07-Present)
Vice Secretary General & Director of the Liaison Committee, KASL (2019.12-2021.12)
Associate Editor, Gut and Liver (2021.12-Present)

RESEARCH INTERESTS

Hepatocellular carcinoma, immunotherapy, gut microbiome, biomarker

REPRESENTATIVE PUBLICATIONS

1. Kim SC, Kim DW, Cho EJ, Lee JY, Kim J, Kwon C, Kim-Ha J, Hong SK, Choi Y, Yi NJ, Lee KW, Suh KS, Kim W, Kim W, Kim H, Kim YJ, Yoon JH, Yu SJ, Kim YJ. A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma. Mol Cancer 2023 Oct 6;22(1):164.
2. Yu SJ, Ma C, Heinrich B, Brown ZJ, Sandhu M, Zhang Q, Fu Q, Agdashian D, Rosato U, Korangy F, Greten TF. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. J Hepatol. 2019 Mar;70(3):449-457.
3. Yu SJ, Kwon JH, Kim W, Yoon JH, Lee JM, Lee JY, Cho EJ, Lee JH, Kim HY, Jung YJ, Kim YJ. Initial Alpha-Fetoprotein Response Predicts Prognosis in Hepatitis B-related Solitary HCC Patients After Radiofrequency Ablation. J Clin Gastroenterol. 2017 Aug 8. doi: 10.1097/MCG.0000000000000841. [Epub ahead of print]
4. Kim H, Yu SJ, Yeo I, Cho YY, Lee DH, Cho Y, Cho EJ, Lee JH, Kim YJ, Lee S, Jun J, Park T, Yoon JH, Kim Y. Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS). Mol Cell Proteomics. 2017 Jul;16(7):1312-1323.
5. Won JK, Yu SJ, Hwang CY, Cho SH, Park SM, Kim K, Choi WM, Cho H, Cho EJ, Lee JH, Lee KB, Kim YJ, Suh KS, Jang JJ, Kim CY, Yoon JH, Cho KH. Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. Hepatology. Hepatology. 2017 Sep;66(3):855-868.

Speaker

Tetsuo Takehara

AFFILIATION / INSTITUTION
Kansai Rosai Hospital

POSITION
Director General

BRIEF INTRODUCTION
Tetsuro Takehara graduated from Osaka University School of Medicine with his M.D. degree and received his Ph.D. degree from Osaka University in 1993. He studied at the Gastrointestinal Unit, Massachusetts General Hospital, USA, as a postdoctoral fellow for three years from 1998, became Associate Professor of Molecular Therapeutics at Osaka University Graduate School of Medicine in 2001, and then Associate Professor of Gastroenterology and Hepatology. In 2011, he became Professor of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine; from 2021, he served as Director of Osaka University Hospital for two years. He is currently Director General, Kansai Rosai Hospital, Japan.
He has conducted outstanding basic and clinical research in the fields of hepatitis, cirrhosis and liver cancer, publishing more than 500 papers in high-impact international journals. In 2017, he received the Oda Award, the highest award of the Japan Society of Hepatology (JSH). He served as President of the Annual Meeting of JSH in 2020, of the Japanese Society of Gastroenterology (JSGE) in 2021 and of the Japanese Society of Internal Medicine in 2025, and will chair the 29th Congress of JSH in JDDW 2025.
From 2018, he is the current Director General, JSH.

PROFESSIONAL CAREER
Clinical Professor, Department of Internal Medicine & Liver Research Institute, SNU College of Medicine (2011.03-Present)
Visiting Scientist, NCI, NIH (Bethesda, MD, USA) (2016-2018)
Director of the Planning Committee, KASL (2023.12-Present)
Academy Affairs Director, KLCA (2022.07 ~ Present)
Vice Secretary General & Director of the Liaison Committee, KASL (2019.12-2021.12)
Associate Editor, Gut and Liver (2021.12-Present)

RESEARCH INTERESTS
Hepatitis, Cirrhosis, Liver Cancer

REPRESENTATIVE PUBLICATIONS
1. Kudo S, Takehara T, et al. Collaborative orchestration of BH3-only proteins governs Bak/Bax-dependent hepatocyte apoptosis under antiapoptotic protein-deficiency in mice. Cell Death Differ. in press.
2. Shigeno S, Takehara T, et al. Intrahepatic exhausted antiviral immunity in an immunocompetent mouse model of chronic hepatitis B. Cell Mol Gastroenterol Hepatol. 2025;19(1):101412.
3. Furuse J, Takehara T, et al. A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy. Clin Cancer Res. 2024 Sep 13;30(18):3990-3995.
4. Kumazaki S, Takehara T, et al. Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis. Aliment Pharmacol Ther. 2024 Aug;60(3):327-339.

How to do wet bench research and manage your lab?

Tetsuo Takehara

Medical research conducted by physician-scientists is not just basic bench research. However, wet bench research is essential to determine the causes of disease and to question the cause-and-effect relationships of clinically observed conditions. Bedside questions need to be applied to bench research, and bench results need to be applied to the bedside.

So first there has to be a good clinical question that leads to a hypothesis, which is then tested in animal models and cultured cells. However, events demonstrated in model system do not necessarily occur in human disease, so human samples must be analyzed as appropriate. Analysis of human samples has also traditionally been carried out as wet bench research, but, more recently, it has become possible to use publicly available data for analysis, as is the case with single-cell analysis. In general, it is not possible to prove causality in human samples, but it is possible to infer whether or not a causal relationship found in model animals or cultured cells is valid from correlative data in human samples. Once a therapeutic target has been identified by such a process, there is a long, long road of translational research before it can be put to practical use. The same applies to biomarker development, where the utility of a biomarker must be demonstrated through clinical research. However, even research that does not lead to practical applications (which is by far the most common) is valuable because it expands scientific knowledge, and as scientists it is important to respect this.

In this context, running a laboratory requires a department for the appropriate collection and statistical analysis of clinical data, and the creation of a wet bench research environment (including the operation of animal facilities) with state-of-the-art equipment. However, setting up such a laboratory requires a lot of money and manpower, so it is necessary to decide which part of the laboratory to start with. This is a matter of taste for each scientist. After starting as PI of the lab, he/she has to determine what is true from the daily research data provided by the lab members and take it step by step to publish valuable scientific papers. Such an achievement leads to the next round of research funding, which in turn leads to the gradual development of the lab. A good lab needs clinical questions (ideas), people (researchers), money (grants) and an eye for science.

Moderator

Ming-Lung Yu

AFFILIATION / INSTITUTION
Kaohsiung Medical University

POSITION
President

BRIEF INTRODUCTION
Ming-Lung Yu graduated with a Ph.D. from the Institute of Medical Science, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. He is now the President of Kaohsiung Medical University(KMU) and a chair professor at the College of Medicine, KMU, Taiwan. He is also an adjunct chair professor at National Sun Yat-sen University(NSYSU). In 2022 to 2024, he was the dean of the College of Medicine, Center of Excellence for Metabolic Associated Fatty Liver Diseases and Senior Vice President of National Sun Yat-sen University(NSYSU), Kaohsiung, Taiwan.

Prof. Yu, a board-certified internist and gastroenterologist, currently teaches at the KMU and a Kaohsiung Medical University Hospital visiting staff. Professor Yu's research interests in the epidemiology and natural history of viral hepatitis have led him to publish more than 500 scientific original and review articles. He also holds various editorial roles, including the Distinguished Reviewer of JAMA Internal Medicine, the Consulting Editor of Clinical and Molecular Hepatology, the Academic Editor of PLoS ONE, the Associate Editor of the World Journal of Gastroenterology and a member of the editorial board of Hepatology, Kaohsiung Journal of Medical Science, and the Journal of Infectious Diseases. He was a Visiting Professor at the Liver Center, Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. He has served as the Senior Vice President at KMU, Superintendent at Kaohsiung Municipal Ta-Tung Hospital and the Vice President at Kaohsiung Medical University Hospital, both in Taiwan. Taken collectively, based on his achievements and contribution to HCV research, he is invited as a critical member of APASL and TASL HCV guidelines, policy-makers, and consulting experts on the Prevention of HBV, HCV of Health Promotion Administration, Ministry of Health and Welfare in Taiwan.

RESEARCH INTERESTS
1.Epidemiology, mechanism, translational medicine of metabolic abnormal fatty liver and new drug development
2.Molecular epidemiology of hepatitis C virus infection in Taiwan 3.Host epigenetic/genetic studies in chronic hepatitis C patients 4.Personalized therapy of patients with acute and chronic hepatitis C 5.Pathogenesis and treatment of hepatocellular carcinoma 6.Molecular/epigenetic/genetic studies of hepatocellular carcinoma 7.The effect of mass hepatitis B virus vaccination in Taiwan 8.Treatment of chronic hepatitis B patients

REPRESENTATIVE PUBLICATIONS
1. 2023-Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
2. 2022-Towards a safe hospital_ hepatitis C in-hospital micro-elimination program (HCV-HELP study)
3. 2020-Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C)
4. 2020-Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection
5. 2020-Extrahepatic Malignancy Among Patients with Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Speaker

Won Kim

AFFILIATION / INSTITUTION

Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center

POSITION

President

EDUCATIONAL

1991-1997 Bachelor's degree, Seoul National University College of Medicine

2000-2002 Master's degree, Seoul National University College of Medicine

2005-2007 Doctoral degree, Seoul National University College of Medicine

2020-now Professor, Seoul National University College of Medicine

2018-2019 Director of Research Committee, Korean Liver Cancer Association

2022-2023 Director of Research and Project Committee, Korean Association for the Study of Liver

2024-now Director of Publication Committee, Korean Association for the Study of Liver

2024-now Editor-in-Chief, Clinical and Molecular Hepatology (IF=14)

2023-now President, KASL-Alcohol-Related Problem Study Group

RESEARCH INTERESTS

Integrated multi-omics approach for precision medicine in MASH

REPRESENTATIVE PUBLICATIONS

1. Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease. JAMA Internal Medicine. (2024)
2. Interaction effect between NAFLD severity and high carbohydrate diet on gut microbiome alteration and hepatic de novo lipogenesis. Gut Microbes (2022)
3. Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease. Journal of Hepatology (2021)
4. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nature Communication (2020)
5. Overproduction of inter--trypsin inhibitor heavy chain 1 after loss of G13 in liver exacerbates systemic insulin resistance in mice. Science Translational Medicine (2019)

How to publish high-impact papers in good journals?

Won Kim

Publishing in high-impact journals remains a key aspiration and challenge for researchers in the biomedical sciences. This lecture provides practical guidance and editorial insights into navigating the complex process of preparing, submitting, and successfully publishing high-quality manuscripts, particularly in the field of liver research. Drawing from extensive experience as both a researcher and editorial board member, the presentation addresses essential strategies for enhancing publication success.

The first segment underscores the importance of understanding the target journal's scope, aims, and recent publications to ensure alignment with editorial expectations. High-impact journals prioritize originality, scientific rigor, innovation in methodology, and relevance to clinical or translational practice. Selecting a meaningful research problem—ideally novel, technically challenging, and clinically significant—is emphasized as foundational. In many cases, identifying the right problem represents the most critical phase of the research process.

The lecture then outlines key components of effective manuscript preparation, including crafting a concise and informative title and abstract, presenting clear and interpretable data, and providing a robust discussion contextualized within current literature. Emphasis is placed on ethical compliance, methodological transparency, appropriate referencing, and thoughtful responses to peer review.

Common pitfalls leading to desk or post-review rejection are reviewed, with illustrative examples. Frequent causes include lack of novelty, misalignment with journal scope, poor writing quality, inadequate literature review, methodological flaws, and insufficient discussion. Specific attention is given to issues such as overstatement of conclusions, absence of statistical significance, and failure to validate findings in independent cohorts.

From an editor's perspective, the lecture elaborates on what differentiates a competitive manuscript: scientific excellence, methodological innovation, human disease relevance, and clarity of message. Conversely, limitations such as overreliance on cell lines, single animal models, descriptive findings lacking mechanistic insight, and incremental advances often lead to rejection.

Finally, the talk concludes with actionable tips to enhance acceptance chances: writing a persuasive cover letter, following author guidelines precisely, seeking feedback from colleagues, and maintaining professionalism in response to reviewers. By understanding and addressing the common reasons for manuscript rejection, researchers can improve their scholarly writing and optimize their publication outcomes.

Moderator



Tetsuo Takehara

AFFILIATION / INSTITUTION

Kansai Rosai Hospital

POSITION

Director General

BRIEF INTRODUCTION

Tetsuro Takehara graduated from Osaka University School of Medicine with his M.D. degree and received his Ph.D. degree from Osaka University in 1993. He studied at the Gastrointestinal Unit, Massachusetts General Hospital, USA, as a postdoctoral fellow for three years from 1998, became Associate Professor of Molecular Therapeutics at Osaka University Graduate School of Medicine in 2001, and then Associate Professor of Gastroenterology and Hepatology. In 2011, he became Professor of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine; from 2021, he served as Director of Osaka University Hospital for two years. He is currently Director General, Kansai Rosai Hospital, Japan.

He has conducted outstanding basic and clinical research in the fields of hepatitis, cirrhosis and liver cancer, publishing more than 500 papers in high-impact international journals. In 2017, he received the Oda Award, the highest award of the Japan Society of Hepatology (JSH). He served as President of the Annual Meeting of JSH in 2020, of the Japanese Society of Gastroenterology (JSGE) in 2021 and of the Japanese Society of Internal Medicine in 2025, and will chair the 29th Congress of JSH in JDDW 2025.

From 2018, he is the current Director General, JSH.

RESEARCH INTERESTS

Hepatitis, Cirrhosis, Liver Cancer

REPRESENTATIVE PUBLICATIONS

1. Kudo S, Takehara T, et al. Collaborative orchestration of BH3-only proteins governs Bak/Bax-dependent hepatocyte apoptosis under antiapoptotic protein-deficiency in mice. Cell Death Differ. in press.
2. Shigeno S, Takehara T, et al. Intrahepatic exhausted antiviral immunity in an immunocompetent mouse model of chronic hepatitis B. Cell Mol Gastroenterol Hepatol. 2025;19(1):101412.
3. Furuse J, Takehara T, et al. A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy. Clin Cancer Res. 2024 Sep 13;30(18):3990-3995.
4. Kumazaki S, Takehara T, et al. Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis. Aliment Pharmacol Ther. 2024 Aug;60(3):327-339.

Speaker

Ming-Lung Yu

AFFILIATION / INSTITUTION
Kaohsiung Medical University

POSITION
President

BRIEF INTRODUCTION
Ming-Lung Yu graduated with a Ph.D. from the Institute of Medical Science, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. He is now the President of Kaohsiung Medical University(KMU) and a chair professor at the College of Medicine, KMU, Taiwan. He is also an adjunct chair professor at National Sun Yat-sen University(NSYSU). In 2022 to 2024, he was the dean of the College of Medicine, Center of Excellence for Metabolic Associated Fatty Liver Diseases and Senior Vice President of National Sun Yat-sen University(NSYSU), Kaohsiung, Taiwan.

Prof. Yu, a board-certified internist and gastroenterologist, currently teaches at the KMU and a Kaohsiung Medical University Hospital visiting staff. Professor Yu's research interests in the epidemiology and natural history of viral hepatitis have led him to publish more than 500 scientific original and review articles. He also holds various editorial roles, including the Distinguished Reviewer of JAMA Internal Medicine, the Consulting Editor of Clinical and Molecular Hepatology, the Academic Editor of PLoS ONE, the Associate Editor of the World Journal of Gastroenterology and a member of the editorial board of Hepatology, Kaohsiung Journal of Medical Science, and the Journal of Infectious Diseases. He was a Visiting Professor at the Liver Center, Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. He has served as the Senior Vice President at KMU, Superintendent at Kaohsiung Municipal Ta-Tung Hospital and the Vice President at Kaohsiung Medical University Hospital, both in Taiwan. Taken collectively, based on his achievements and contribution to HCV research, he is invited as a critical member of APASL and TASL HCV guidelines, policy-makers, and consulting experts on the Prevention of HBV, HCV of Health Promotion Administration, Ministry of Health and Welfare in Taiwan.

RESEARCH INTERESTS
1.Epidemiology, mechanism, translational medicine of metabolic abnormal fatty liver and new drug development
2.Molecular epidemiology of hepatitis C virus infection in Taiwan 3.Host epigenetic/genetic studies in chronic hepatitis C patients 4.Personalized therapy of patients with acute and chronic hepatitis C 5.Pathogenesis and treatment of hepatocellular carcinoma 6.Molecular/epigenetic/genetic studies of hepatocellular carcinoma 7.The effect of mass hepatitis B virus vaccination in Taiwan 8.Treatment of chronic hepatitis B patients

REPRESENTATIVE PUBLICATIONS
1. 2023-Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
2. 2022-Towards a safe hospital_ hepatitis C in-hospital micro-elimination program (HCV-HELP study)
3. 2020-Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C)
4. 2020-Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection
5. 2020-Extrahepatic Malignancy Among Patients with Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Leadership skills: How to build and manage your team? How to become a mentor?

Ming-Lung Yu

Effective leadership is a critical factor in the development of high-performing teams, particularly within the healthcare sector, where interdisciplinary collaboration influences patient outcomes. This presentation examines key leadership competencies required to build, manage, and mentor successful teams in clinical and academic contexts. Drawing from the case of Taiwan's leading hepatitis treatment team, it highlights the impact of vision, decision-making, and mentorship on both medical performance and institutional development.

Core leadership elements include setting a clear and inspiring vision, making timely and evidence-based decisions, and fostering trust and influence among team members. Effective team formation involves aligning individual strengths with defined roles, selecting personnel with both technical and interpersonal skills, and establishing measurable, shared goals. A transparent and collaborative team culture is essential, especially in high-stakes environments like medicine.

Mentorship is presented as a foundational leadership responsibility, extending beyond skills development to include emotional support and long-term career guidance. Structured mentorship programs are shown to enhance clinical competence and research output while simultaneously preparing junior staff for leadership roles. Encouraging involvement in strategic decisions also fosters leadership succession and team resilience.

The case study illustrates practical applications of these principles: recruiting multidisciplinary experts, integrating AI and telemedicine into care models, and securing public-private funding partnerships. These efforts collectively contributed to significant advancements in hepatitis care and reductions in liver disease mortality. Ultimately, the presentation underscores that effective leadership is not limited to administrative tasks—it involves vision, influence, and the ability to cultivate future leaders capable of transforming healthcare outcomes.